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Abstract 
 
Peripheral neuropathies, as the result of nerve damage, are characterized by pain, 
numbness, and tingling in the extremities and slow nerve conduction. Chemotherapy-
induced peripheral neuropathy is a major dose-limiting side effect of many other 
commonly used chemotherapeutic agents, including platinum drugs, taxanes, epothilones 
and vinca alkaloids, but also newer agents such as bortezomib. 
Bortezomib (VELCADE) is a boronic acid dipeptide, which causes a selective blockade of 
proteasome activity. Bortezomib-induced peripheral neuropathy is an important clinical 
complication, often difficult to manage or reverse, whose treatment usually involves dose 
reduction, interruption, or cessation of therapy. 
Though many animal models of chemotherapy-induced peripheral neuropathy have been 
designed, knowledge concerning the mechanisms that may underlie neurochemical 
changes accompanying the onset of bortezomib-induced peripheral neuropathy is still poor. 
In this study, to analyze the possible neurochemical changes occurring in primary sensory 
neurons, the effects of a single-dose intravenous administration and a well-established 
“chronic” schedule (three times/week for 8 weeks) in a rat model of bortezomib-induced 
peripheral neuropathy have been examined. 
The transient.receptor.potential.vanilloid.type.1 (TRPV1) channel and sensory 
neuropeptides calcitonin.gene-related.peptide (CGRP) and substance.P (SP) were studied 
in L4-L5 dorsal root ganglia (DRGs), spinal cord and sciatic nerve using western blot 
(WB), immunohistochemistry, and reverse transcriptase-polymerase chain reaction (RT-
PCR). Behavioral measures, performed at the end of the chronic bortezomib-treatment, 
confirmed a reduction of the mechanical nociceptive threshold, whereas no difference 
occurred in the thermal withdrawal latency. In the DRGs, TRPV1-, CGRP- and SP-
immunoreactive neurons were mostly small- and medium-sized and the proportion of 
TRPV1- and CGRP-labeled neurons increased after treatment. A bortezomib-induced 
increase in density of TRPV1- and CGRP-immunoreactive innervation in the dorsal horn 
was also observed. WB analysis showed a relative increase of TRPV1 in DRG and spinal 
cord after both acute and chronic bortezomib-administration. Comparative RT-PCR 
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revealed a decrease of TRPV1 and CGRP mRNA relative levels after chronic treatment. 
The characterization of this animal model of peripheral neuropathy suggests that the 
neurochemical changes occurring in populations of DRG neurons that are likely involved 
in pain transmission appear to be an important component of the sensory neuropathy 
induced by the bortezomib-treatment and may represent the outcome of the molecular 
machine activated by the drug during the onset and persistence of bortezomib-induced 
neuropathic pain. 
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1. Introduction 
 
1.1 Peripheral neuropathy  
 
When a patient presents with symptoms of distal numbness, tingling and pain, or 
weakness, the first challenge to the physician is to determine whether the symptoms are the 
result of peripheral neuropathy (PN) or of a CNS lesion (England et al., 2005). Peripheral 
neuropathy is a general term that indicates any disorder of the peripheral nervous system 
and affects both sensory and motor fibers (Hughes, 2002; Federici and Boulis, 2009). 
Damage to sensory nerves, in the PN early stages, can produce rapidly progressive 
symptoms. Among the different settings, distal symmetrical polyneuropathy is the most 
common one; it develops by affecting toes and soles of the feet first and often occurs in a 
“stocking and glove” distribution. Thus, in diabetic polyneuropathy, the prototype of motor 
and sensory polyneuropathy, sensory abnormalities such as numbness, pain, burning, 
paraesthesia, or disaesthesia in the toes or feet are among the earliest symptoms of 
polyneuropahty (Martyn and Hughes, 1997; England and Aubury, 2004; England et al., 
2005). The severity of nerve fibre impairment depends on a number of variables, among 
which the distance from the parent cell body appears to be a common finding: the higher 
the distance from the cell soma the higher the nerve fiber damage. A list of typical signs 
and symptoms of peripheral neuropathies (Archer et al., 1983; Lindblom, 1985; Ochoa, 
1996; Backonja, 2003; Marchettini et al., 2006), based on a combination of clinical 
findings, electrophysiological tests, and laboratory investigations is given below: 
 paresthesia, is a sensation of tingling, tickling, prickling, pricking, or burning of a 
person's skin with no apparent long-term physical effect. The manifestation of a 
paresthesia may be transient or chronic.The most familiar kind of paresthesia is the 
sensation known as "pins and needles" or of a limb "falling asleep". 
 dysesthesia, is described as spontaneous or evoked burning pain, often with a 
superimposed lancinating component; special cases of dysesthesia include: 
 hyperalgesia, an increased response to a stimulus which is normally painful; 
 allodynia, pain due to a stimulus which does not normally provoke pain; 
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 hypoesthesia, due to a decreased sensitivity to stimulation or, reversely, 
 hyperesthesia, an increased sensitivity to stimulation.  
Lack of sensation (including loss of proprioception, loss of touch and temperature 
discrimination), areflexia and pain can cause other complications relating to recurrent 
injuries that may go unnoticed (e.g., unawareness of cuts or burns to the skin), and can lead 
to ulcers or poor wound healing. The symptoms of sensory PN can be intermittent or 
continuous and may significantly interfere with quality of life (Sommer, 2003; England et 
al., 2005; Wolf et al., 2012). 
Damage to motor fibers results in decreased control of voluntary movements. Symptoms of 
damage to peripheral motor nerves usually begin as weakness or heaviness of the hands 
and/or feet; over time the numbness may extend proximally, and mild distal muscle 
weakness and atrophy may occur. Damage to motor function can also lead to abnormalities 
in muscle, bone, skin, and other organs (Peltier and Russell, 2002; Hay, 2002; Visovsky 
and Daly, 2004; Hausheer, 2006; Stillman and Cata, 2006; Ripellino et al., 2014). 
Diagnosis of PN requires both a complete assessment of patient conditions to determine 
the extent of the neurological deficit and a thorough anamnesis, and a physical examination 
to determine the possible aetiology (Head, 2006). In fact, a variety of causes such as 
diabetes, alcohol, genetic disease, thyroid dysfunction, metabolic and infectious disease, 
cancer and chemotherapy can be implicated in the pathogenesis of clinical syndrome 
(Kalet and De Angelis, 2009). Chronic polyneuropathy usually evolves in months or years 
and a defining branching point in its evaluation depends on whether it is demyelinating or 
axonal (England and Aubury, 2004). Actual origins of polyneuropathy remain a mistery in 
approximately 50 percent of cases; in the case of chronic polyneuropathy, even after a 
meticulous history, no primary cause is found in 20–25% of patients (England and Aubury, 
2004). However, on the basis of the complex combination of precise anamnesis, 
neurological examination, and electrodiagnostic tests, specific diagnostic possibilities can 
be narrowed to the following few features: - the rate of development and pattern of the 
disease (gradually progressive or relapsing), - the relative involvement of motor and 
sensory fibres, - the relative involvement of large and small sensory fibres (predominantly 
large fibre, predominantly small fibre, or both), and - the electrophysiological findings 
(mainly demyelinating, mainly axonal, or both). Such a characterisation helps limiting the 
probable causes to a controllable degree. For example, a chronic, steadily progressive 
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distal symmetrical sensori–motor polyneuropathy with mainly axonal features is 
presumably secondary to systemic or endocrine diseases, metabolic disorders, medications 
or toxins. Instead, a longstanding chronic, largely motor distal symmetrical polyneuropathy 
with evenly demyelinating features is almost certainly an inherited polyneuropathy (eg, 
Charcot-Marie-Tooth disease). 
Once the lesion has been localized to peripheral nerves, the next step is to diagnose the 
degree of nerve fiber involvement: single nerve root, multiple nerve roots, or a peripheral 
nerve plexus (LoMonaco et al., 1992; Kannarkat, 2007; Azhary et al., 2010). Infact, 
another very common way to classify disorders of peripheral nerves takes into account the 
clinico-pathological pattern of nerve damage and includes:  
 FOCAL PERIPHERAL NEUROPATHY, that is a discrete lesion to a nerve, be it a spinal 
nerve root, a plexus, an individual major nerve trunk, or a branch from such a 
nerve. The neurological deficit is restricted to the motor and sensory territories 
supplied by the damaged nerve. 
 MONONEUROPATHY MULTIPLEX, when two or more individual nerves or branches 
are involved. Thus, the symptoms and signs are restricted to the territories of these 
damaged nerves. Which of these types of peripheral neuropathies produce bladder, 
bowel or sexual dysfunction (Quasthoff et al., 2002; England and Asbury 2004; 
Armstrong et al., 2005; England et al., 2005).  
 POLYNEUROPATHY, i.e. a generalized nerve damage. The peripheral nerves are 
affected symmetrically and, usually, the longest nerve fibers are damaged first and 
maximally. Thus, the symptoms and signs involve both feet first, and as the 
disorder progresses, the hands are also both involved. 
Taken as a whole, neuropathic pain is a debilitating condition that affects a large sector of 
the population, an estimated 50 million Americans, and represents a burden in terms of 
health care expenses and lost productivity (Pasnoor et al., 2013). 
A best estimate of population prevalence of pain with neuropathic characteristics is likely 
to lie between 6.9% and 10% (Van Hecke et al., 2013). One reason for the high prevalence 
rate of chronic neuropathic pain is the absence of effective treatments (Smith and Torrance, 
2012). It is still unclear why neuropathies of apparently the same aetiology can be painful 
or painless, advances in the standardization of assessment of patients with painful 
neuropathies are beginning to have an impact on the design of relevant clinical treatments. 
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In late 2000, the US Congress passed into law a provision that declared 2001–2010 as the 
Decade of Pain Control and Research. Despite extensive efforts, the mainstay of analgesics 
for chronic pain is still morphine and its analogs, whose long term use is limited by 
important side effects (such as the development of tolerance, addiction, hyperalgesia, 
sedation, respiratory depression, and constipation) leading to premature death (Premkumar, 
2010). 
Overall, leading progress has been made in the understanding of cellular and molecular 
changes underlying the onset of peripheral neuropathy. However, both acute and chronic 
pain results from the engagement of highly plastic molecules and circuits, the 
neurochemical basis of which in the pathophysiology of a drug-induced painful sensory 
neuropathy are the focus of this study (Sommer, 2003; Colleoni and Sacerdote, 2010; 
Wolf, 2010; Ripamonti, 2012; Brix et al., 2013). 
 
1.1.1 Neuropathic pain 
 
Neuropathic pain occurs as a result of neuronal plasticity and neuronal rewiring following 
traumatic, viral, surgical, metabolic, or drug-induced damage to the neurons (Premkumar, 
2010). Its onset still remains an enigma. It differs from the classical senses (vision, hearing, 
touch, taste, and smell) because it has both a discriminative component and a graded 
motivational or behavioral drive (Craig, 2003). 
Advances in molecular biology techniques and the subsequent discovery of specific 
molecules involved in pain processing have contributed to a better understanding of pain 
(Fürst, 1999; Scholz and Woolf, 2002; Ueda and Rashid, 2003; Ueda, 2008). 
In 2011, neuropathic pain has been defined by the International Association for the Study 
of Pain (IASP) as “pain caused by a lesion or disease of the somatosensory system” 
(Jensen, 2011). Neuropathic pain is different from pain messages carried along healthy 
nerves from damaged tissue (eg a fall, cut, or arthritic knee) and, clinically, is treated by 
different drugs than pain from damaged tissue. To distinguish between nociception and 
pain is basic to understand sensory systems. Pain is a survival mechanism that supplies a 
warning sign of ongoing or impending tissue damage (Usunoff et al., 2006; Basbaum et 
al., 2009). Thus, nociception is the process by which non electrical signals (thermal, 
mechanical, or chemical) are converted to electrochemical ones by a subpopulation of 
peripheral nerve fibers, called nociceptors. By contrast, neuropathic pain involves direct 
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nerve stimulation. Another factor that distinguishes neuropathic pain from nociceptive pain 
is the different prognosis; in fact, most people with nociceptive pain (for example, after 
surgery) recover, whereas injury to a major nerve (for example, plexopathy or limb 
amputation) often generates persistent pain (Cohen and Mao, 2014). 
Physiologically, pain has been broadly categorized into 3 categories (Scholz and Woolf, 
2002):  
 ACUTE or PHYSIOLOGICAL PAIN, 
 INFLAMMATORY PAIN, 
 CHRONIC PAIN. 
ACUTE PAIN is experienced at the moment of an insult. It is an unpleasant sensory 
experience; it is part of the above mentioned rapid warning relay, evoked by stimulation of 
nociceptors specialized in responding only to stimuli approaching or exceeding harmful 
intensity responses. Lack of the ability to experience pain, as in the rare condition of 
congenital insensitivity to pain with anhidrosis (Ferrell, 2000; Axelrod and Hilz, 2003), 
can cause very serious health problems such as self-mutilation, auto-amputation, and 
corneal scarring. 
INFLAMMATORY PAIN is associated with tissue damage and the ensuing inﬂammatory 
process, and is adaptive because it elicits physiological responses that promote healing. In 
inflammatory nociceptive pain, inflammation may cause damage to the neurons and 
produce neuropathic pain (Medzhitov, 2008). 
CHRONIC PAIN is defined as pain lasting longer than 3 months, outlasting the usual healing 
process and generally falls into two subtypes:  
 NOCICEPTIVE PAIN, caused by damage to body tissue and typically described as a 
sharp, aching, or throbbing pain. This kind of pain is often due to benign pathology; 
 NEUROPATHIC PAIN occurs when there is an actual nerve damage. Innumerable 
diseases may be the culprits, examples include autoimmune disease (e.g., multiple 
sclerosis), metabolic diseases (e.g., diabetic neuropathy), infections (e.g., shingles 
and the consequent postherpetic neuralgia; HIV infections), vascular disease 
(stroke), trauma, cancer, and anticancer treatments such as chemotherapeutics or 
cytotoxic drugs (Woolf and Mannion, 1999; Bridges et al., 2001; Sah et al., 2003; 
Chen et al., 2004).  
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The presence of neuropathic pain is often characterized by stimulus-independent persistent 
pain or abnormal sensory perception of pain such as allodynia, pain following a normally 
non-painful tactile or thermal stimulus, and hyperalgesia, exaggerated pain sensations as a 
result of exposure to mildly noxious stimuli (Woolf and Mannion, 1999; Bridges et al., 
2001). 
The profound differences between acute and chronic pain emphasize the fact that pain is 
not generated by an immutable hardwired system, but rather implies the engagement of 
highly plastic molecules and circuits involving peripheral sensitization, spinal and 
supraspinal mechanisms, cortical reorganization (Basbaum et al., 2009). Contextually, a 
large variety of changes at the level of components such as transduction, conduction, 
transmission, modulation and perception intervene in sensory processing in pain pathway 
(Gatchel et al., 2007). 
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1.1.2 Chemotherapy-induced peripheral neuropathy  
 
Beside bone marrow suppression and renal toxicity, the neurotoxic side effects of the 
chemotherapeutic agents are very often the reason for early cessation of anti-tumour 
therapy or change of the dose regimen, all of which compromise the success of cancer 
treatment (Quasthoff and Hartung, 2002; Mantyh, 2006). In addition, this can interfere 
with key aspects of quality of life including physical, social, and role functioning and 
emotional well being (Ostchega and Fox, 1988; Bakitas, 2007). 
Chemotherapy-induced PN is a major dose-limiting side effect observed after clinical 
treatment with the vinca alkaloids, the taxanes, the platinum-derived compounds, suramin, 
thalidomide and the most recently identified proteasome inhibitors. More than 30% of 
patients who receive one of the above anticancer drugs will develop PN (Quasthoff et al., 
2002; Cata et al., 2007; Dick and Flaming, 2010). 
So far, the mechanisms responsible for the development of chemotherapy-induced PN are 
still uncovered. The mechanism of neurotoxicity is not necessarily the same as that of the 
anticancer effect and multiple mechanisms can contribute to the neurotoxicity. Moreover, 
toxicity can affect either the neuronal bodies, and generally they are represented by the 
primary sensory neurons in the dorsal root ganglia, or the axons or both (Krarup-Hansen et 
al., 2007; Albers et al., 2011). 
Generally chemotherapy-induced PN is a group of neuromuscular symptoms that result 
from nerve damage, though several patterns of chemotherapy-induced PN are commonly 
recognized (Visovsky, 2003). Sensory symptoms, such as paresthesias and numbness, 
occurring usually between the first and third cycles of therapy, are the earliest. Motor 
weakness usually develops in a delayed fashion, and this is explained by the fact that 
sensory neurons and axons that transmit pain perception are unmyelinated and lightly 
myelinated fibers and are more susceptible than motor fibers to damage from exogenous 
toxins (Saif and Reardon, 2005). Many chemotherapeutics are believed to cause 
destruction or dysfunction of the myelin sheath that, in turn, may cause parasthesias. Loss 
of vibratory sense, two-point discrimination, and proprioception may also result from 
damage to the myelin sheath (Mantyh, 2006). It is not uncommon for symptoms to persist 
or even develop weeks to months after discontinuation of the chemotherapy. This 
phenomenon, known as “coasting”, was first recognized with the vinca alkaloid vincristine. 
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Vinca alkaloids, such as vincristine, and taxanes, like paclitaxel and docetaxel are 
microtubule stabilizing agents that exert their effects by disrupting mitosis in dividing cells 
(Holland et al., 1973; Boyette-Davis et al., 2013). Suppression of microtubule dynamics 
may cause activation of the mitotic checkpoint triggering apoptosit or reversion to the G-
point phase of the cell cycle (Quasthoff and Hartung, 2002). Since microtubules are 
important for the development and maintenance of neurons, neurotoxicity appears to be 
one of the major side effects (Bhutani et al., 2010; Jordan and Wilson, 2004). Sometimes, 
as after paclitaxel-tratment and on the basis of patient descriptors of pain, a peculiar 
syndrome of subacute aches and pains has been related to nociceptor sensitization 
(Loprinzi, 2011). In the case of platinum-based drug-treatment, the coasting effect has 
been related to their ability to bind to deoxyribonucleic acid (DNA) and form Pt-DNA 
adducts that, in turn, inhibit transcription and induce apoptosis through DNA damage 
recognition pathways (Jung and Lippard, 2007; McWhinney et al., 2007). Oxaliplatin, 
instead, affects voltage-gated sodium-channel kinetics, leading to consequent 
hyperexitability of sensory neurons (Lehky et al., 2004; Binder et al., 2007; Park et al., 
2009; Cavaletti and Marmiroli, 2010; Pachmanet al., 2011). Thus, oxaliplatin-induced 
acute neuropathy is characterized by two electrophysiological hallmarks of peripheral 
nerve hyperexcitability, namely cold-induced paresthesias and jaw tightness. Although, 
from a neurochemical point of view, these symptoms have led to hypothesize that the 
sensitization of the Transient Receptor Potential (TRP) channels type M8 and/or A1 
receptors in primary afferent neurons underlies the acute oxaliplatin-induced pain (Binder 
et al., 2007; Stengel and Baron, 2009), interestingly mouse model of cisplatin and 
oxaliplatin-induced painful neuropathy using knock-down TRP type V1 mice, suggests 
that TRPV1 also participates in development of mechanical hyperalgesia in platinum drug-
induced pain (Ta et al., 2010). 
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1.1.3 Bortezomib-induced peripheral neuropathy  
 
Bortezomib (VELCADE; formerly PS-341, LDP-341, MLN341) is a boronic acid 
dipeptide (cfr Fig. 1a). It is a novel first-in-class proteasome inhibitor, which specifically 
blocks the chymotryptic site of the 26S proteasome and therefore acts by disrupting 
various cell signaling pathways, thereby leading to cell cycle arrest, apoptosis, and 
inhibition of angiogenesis (Delcros et al., 2003; Wu and Shi, 2013). Since numerous 
proteins are target of the proteasome-mediated degradation, multiple cellular processes are 
affected by proteasome inhibition (Ciechanover, 1998). Therefore, the effectiveness of 
bortezomib in arresting cell growth in different cancers probably involves a variety of 
molecular mechanisms. Extensive preclinical research has contributed to elucidate the 
bortezomib mechanism of action and to examine its activity, both as a single agent and in 
combination with other anticancer drugs, in a wide variety of solid and hematologic tumors 
and cancer models (Adams, 2004). 
In cell cultures, bortezomib has been shown to induce apoptosis in both hematologic and 
solid tumor malignancies, including myeloma (Hideshima et al., 2001), mantle cell 
lymphoma (Pham et al., 2003), and non-small cell lung (Ling et al., 2003), ovarian 
(Frankel et al., 2000), pancreatic (Shah et al., 2001; Bold et al., 2001), prostate (Frankel et 
al., 2000; Adams et al., 2002), and head and neck cancer (Sunwoo et al., 2001). 
As a whole, proteasome inhibition appears to induce apoptosis or to increase cell 
sensitivity to apoptosis by shifting the balance between pro- and antiapoptotic signals 
(Adams, 2003). Though the mechanisms by which bortezomib induces apoptosis are not 
yet fully unveiled, it has been shown that proteasome inhibition is associated with the 
stabilization of pro- and antiapoptotic proteins (cfr Fig. 1b), including cyclin-dependent 
kinase inhibitors (e.g., p21 and p27) and tumor suppressors (e.g., p53) (An et al., 1998; 
MacLaren et al., 2001; Shah et al., 2001). Proteasome inhibition also interferes with the 
unfolded protein response, thereby causing endoplasmatic reticulum stress (ER-stress) and 
increased apoptosis (Lee et al., 2003). The involvement of regulatory proteins in apoptosis 
differs according to cell type. Certainly, the transcriptional activator NF-κB has been 
recognized a central role in mediating many of the effects of proteasome inhibition. Beside 
its involvement in inflammation and immune responses, NF-κB and its signaling pathways 
were also recently implicated in tumor development (Karin et al., 2002). Under normal 
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conditions, NF-κB is bound to its inhibitor IκB, and transcriptional activation of genes by 
NF-κB is suppressed. In response to cellular stresses, IκB is degraded by the proteasome 
and NF-κB is released, activating transcription of genes for growth factors, stress response 
enzymes, cell adhesion molecules, and apoptosis inhibitors (Karin et al., 2002). By 
contrast, bortezomib inhibits NF-κB activation through proteasome inhibition though 
inhibition of NF-κB activation does not completely explain its anticancer activity (Cusack 
et al., 2001; Hideshima et al., 2001; Hideshima et al., 2002). 
Bortezomib monotherapy, approved by the U.S. FDA in 2003 for the treatment of 
refractory multiple myeloma (MM), is effective in the treatment of recurrent and newly 
diagnosed multiple myeloma (Richardson et al., 2003; San Miguel et al., 2008), and of 
recurrent mantle cell lymphoma (Kane et al., 2007).  
However, as already stated above, bortezomib-treatment shows a significant dose-limiting 
toxicity by inducing a severe painful PN, typically occurring as earliest as the first cycles 
of drug administration and reaching a plateau at cycle 5, whose onset mechanisms appear 
to be multifactorial (Richardson et al., 2006; Chaudhry et al., 2008). Studies in animal 
models demonstrate that bortezomib exerts its effects by causing a significant neuronal 
dysfunction characterized by interfering with transcription, nuclear processing and 
transport, and cytoplasmic translation of mRNAs in DRG neurons (Casafont et al., 2009). 
Neurophysiological and histopathological findings show that the bortezomib-induced 
neuronopathy is dose-dependent and mostly due to a reduction of large and C-fibers. 
Abnormal vesicular inclusion bodies appear to be a hallmark of bortezomib-affected 
unmyelinated axons together with mitochondrial and endoplasmic reticulum damage (Pei 
et al., 2004; Landowski et al., 2005; Ravaglia et al., 2008). As for the molecular pathways 
actually involved in the bortezomib-induced neuronopathy they are far from being clearly 
defined. One of the inferring is that a potential role in the genesis of bortezomib-induced 
PN is played by the dysregulation of the neurotrophin machinery, triggered either by the 
activation of the mitochondrial-based apoptotic pathway or by the inhibition of the nerve 
growth factor-mediated neuron survival (via interference with the NF-κB pathway), plays 
(Hacker et al., 2006; Miller et al., 2009; Piperdi et al., 2011). 
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Figure 1 a, b. Mechanism of action of bortezomib 
A: molecular structure of bortezomib, Velcade commercial compound. 
B: schematic representation of intracellular effects of bortezomib. The activation of transcription factor 
nuclear factor-κB (NF-κB) is dependent on proteasome activity. NF-κB is normally sequestered in the 
cytoplasm and rendered inactive by its inhibitor protein IκB. However, numerous stimuli, including cell 
stressors, prompt the phosphorylation and subsequent proteasomal degradation of IκB, thus allowing the 
release of NF-κB. The transcription factor then translocates to the nucleus and initiates the transcription of a 
wide range of genes, including those involved in cell survival, cell adhesion, and cytokine signaling. The 
boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity. In 
normal cells, the proteasome regulates protein expression and function by degradation of ubiquitylated 
proteins, and also cleanses the cell of abnormal or misfolded proteins. Proteasome inhibition may prevent 
degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells 
dependent upon suppression of pro-apoptotic pathways. Recently, it was found that bortezomib caused a 
rapid and dramatic change in the levels of intracellular peptides that are produced by the proteasome. Some 
intracellular peptides have been shown to be biologically active, and so the effect of bortezomib on the levels 
of intracellular peptides may contribute to the biological and side effects of the drug (original image from 
Sanchez-Serrano, 2009). 
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1.2 Dorsal Root Ganglia 
 
Afferent sensory fibers coalesce together to enter the spinal cord via the dorsal root. 
Primary afferent neuronal cell bodies are grouped in a swelling along the dorsal root 
extension, just outside the spinal canal and lying near or within the intervertebral foramina, 
to form the dorsal root ganglia (DRG). Entering the spinal cord at its dorsal surface in an 
area known as the dorsal root entry zone (DREZ), small, medium-size, and large afferent 
fibers perform their various functions with glutamate serving as the primary 
neurotransmitter (Usunoff et al., 2006). The DRG contain the primary afferent neuronal 
perikarya, each surrounded by the satellite glial cells, nerve fibers and Schwann cells 
(Lieberman, 1976; Hanani, 2005). DRG neurons are pseudo-unipolar, i.e. they emit a 
single axon that, a few tens or hundreds µm from the soma, divides in two branches that 
act as a single axon, often referred to as the distal process and the proximal process. The 
action potential in DRG neurons may initiate in the distal process in the periphery, bypass 
the cell body, and continue to propagate along the proximal process until enters the dorsal 
root and reaches the synaptic terminal in the dorsal horn of the spinal cord (Lawson et al., 
1987; Lawson, 1992; Devor, 1999). A capsule composed of connective tissue and a 
perineurium, similar to that of peripheral nerves, surrounds the entire DRG and keeps the 
microenvironment separate from surrounding extracellular fluid (Olsson, 1990).  
DRG neurons can be classified into various subpopulations based on their anatomy, 
neurochemistry and physiology (Lawson, 1992; Snider and McMahon, 1998; Hunt and 
Mantyh, 2001). The Nissl staining allows to distinguish the DRG neurons into large-light 
and small-dark cells. Large cells show a rather pale and unevenly stained cytoplasm, due to 
aggregations of Nissl substance interspersed with lightly stained regions, contain 
microtubules and a large amount of neurofilaments; they comprise approximately 40% of 
lumbar DRG cells (Usunoff et al., 2006). Large DRG neurons have mostly myelinated 
axons that conduct in the Aα/β range and receive input from peripheral mechanoreceptors 
(Harper and Lawson, 1985; Sommer et al., 1985; LaMotte et al., 1991; Lawson and 
Waddell, 1991; Willis and Coggeshall 1991; LaMotte et al., 1992; Truong et al., 2004). 
The small-dark cells represent the second major group of DRG neurons; they can be 
further subdivided into neuropeptidergic and non neuropeptidergic neurons. The former 
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constitutively express neuropeptides and the calcitonin gene related peptide (CGRP) 
represents the best marker for them.They emit unmyelinated axons, namely C fibres, and 
innervate mainly polymodal nociceptors (McCarthy and Lawson, 1990; Lawson et al., 
1997). The latter, identifiable by using a variety of histochemical markers, have been 
especially characterized by their binding of the lectin Griffonia simplicifolia IB4 (Streit et 
al., 1986) or by their expression of a nonlysosomal fluoride-resistant acid phosphatase 
(FRAP) (Silverman and Kruger, 1988). This group of small-diameter cells (which will be 
referred to as IB4+) also emits unmyelinated axons (C fibres) that are likely to mediate 
nociception (Silverman and Kruger, 1990; Alvarez et al., 1991).  
While these categories are largely histochemically distinct, at the same time there is also 
some degree of overlap among them. Thus, a group that is intermediate in size between the 
large-sized and the small-sized neuropeptidergic ones is represented by CGRP- and 
substance P (SP) -containing cells that are medium-sized and emit finely myelinated, Aδ 
axons. Most of these cells are nociceptors of the high-threshold mechanoreceptor type 
(McCarthy and Lawson, 1990; Lawson et al., 1996, 1997). Further overlap occurs between 
the IB4 binding and CGRP-containing populations (Bennett et al., 1996).  
An additional characterization allows to differentiate DRG neurons on the basis of their 
responsiveness to selective target-derived neurotrophic proteins. Availability of 
neurotrophic proteins, such as nerve growth factor (NGF) and glial cell line-derived 
neurotrophic factor (GDNF), has been directly related to the maintenance of mature 
neuronal phenotype and neuronal ability to react to injury. In this context, non-peptidergic 
cells appear to be regulated by GDNF since they bear ret, the high affinity GDNF receptor, 
whereas peptidergic neurons and large-sized ones, bearing the high affinity trkA receptor, 
are regulated by NGF (Priestley et al., 2002). 
Subsets of both types of small-sized neurons show a range of expression levels of TRPV1 
capsaicin receptor, most likely making them responsive to similar types of noxious stimuli 
(Bennett et al., 1996; Priestley et al., 2002). 
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1.2.1 Nociceptors and nerve fiber classification 
 
The term nociception indicates the reception of input delivered to the central nervous 
system by sensory receptors known as nociceptors, i.e. the peripheral endings of primary 
afferent neurons whose cell bodies are located in the DRG and cranial sensory ganglia. 
Nociceptors provide information about tissue injury, though not all information delivered 
through this system will be perceived as painful (Usunoff et al., 2006; Julius and Basbaum, 
2001). 
Afferent fibers involved in pain transmission can be classified in three types (cfr Table 1), 
according to their structure, degree of myelination, and function: 
 A-beta fibers, or mechanoreceptors, transmit sensory information regarding touch, 
vibration and hair deflection; they are myelinated large-diameter low-threshold 
fibers; they transmit with a conduction velocity of 40-70 m/sec and may contribute 
to the development of pathological pain sensation (Ren, 1996) (cfr Table 1); 
 A-delta fibers respond to noxious mechanical stimulation. They are small-diameter, 
myelinated fibers with slower conduction velocity (5-15 m/sec) compared to A-beta 
fibers; among them are the temperature-sensitive nociceptors which are sensitive to 
intense heat and cold (Cook et al., 1987; Ren, 1996) (cfr Table 1). 
 C-type polymodal nociceptors originate in the epidermis and deep receptors located 
in ligaments, muscles, and connective tissues. They respond to specific chemical 
compounds such as histamine, bradykinin, serotonin, prostaglandins, proteolytic 
enzymes, potassium and acids. These fibers are the smallest and slowest of the 
nociceptors, conducting impulses at approximately 0,5 m/s: C fibers are 
unmyelinated and require intense mechanical, thermal, or chemical stimulation to 
transmit pain impulses. Physiologically, the C-nociceptor responds directly to 
increasing intensity of noxious stimulation -the greater the stimulus strength, the 
more vigorous the response (Besson and Chaouch, 1987). Repeated stimulation, 
however, enhances C-nociceptor responsivity to a given stimulus strength 
(LaMotte, 1984; reviewed by Campbell et al., 1989) (cfr Table 1). 
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Table 1. General classification of nerve fibers. 
Type  Diameter, 
µm 
Conduction 
velocity, 
m/sec 
General Function Myelination 
A-alpha  
13-22 
 
70-120 
alpha-motoneurons, 
muscle spindle primary 
endings, Golgi tendon 
organs, touch 
 
Y 
A-beta  
8-13 
 
40-70 
touch, kinaesthesia, 
muscle spindle secondary 
endings 
 
Y 
A-gamma  
4-8 
 
15-40 
touch, pressure, gamma-
motoneurons 
 
Y 
A-delta  
1-4 
 
5-15 
pain, crude touch, 
pressure, temperature 
 
Y 
B  
1-3 
 
3-14 
preganglionic autonomic  
Y 
 
C 
 
 
0.1-1 
 
0.2-2 
pain, touch, pressure, 
temperature, 
postganglionic 
autonomic 
 
N 
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1.2.2 Cytoarchitecture of the spinal cord dorsal horn 
 
Dorsal horn neurons receive sensory information from primary afferents that innervate the 
skin and deeper tissues of the body and respond to specific types of noxious and non-
noxious stimuli (Todd, 2010). Primary afferents terminate in the dorsal horn with a 
distribution pattern that is determined by the sensory modality they are conveying and the 
body region of innervation, according to a very specific spatial organization (cfr Fig 2). 
The incoming information is processed by complex circuits involving excitatory and 
inhibitory interneurons, and is transmitted to projection neurons for relay to several brain 
areas (cfr Fig 3). 
According to the original description of Rexed (1952; 1964), the spinal gray matter can be 
subdivided into 10 nuclei or laminae. In this setting, the dorsal horn comprises laminae I–
VI, the intermediate zone comprises lamina VII, the ventral horn harbors laminae VIII and 
IX and the periependimal region corresponds to lamina X (cfr Fig 2). 
 
 
Figure 2. Spinal cord trasversal section 
The axons enter the spinal cord by Lissauer’s tract, they immediately divide and travel a short distance of one 
or two segments upward and downward in the spinal cord.before terminating in the external part of the dorsal 
horn The gray matter of the spinal cord is divided into laminae according to Rexed, indicated by roman 
numerals, the most involved in pain sensory pathways ranging from lamina I to VI (Image from 
http://www.studyblue.com) 
  
25 
 
 
Laminae I-VI  
 The dorsomarginal nucleus - Lamina I, capping the dorsal horn, receives many 
afferent fibers carrying pain, temperature, and light touch sensations. Many 
intersegmental pathways arise from this layer that also contributes fibers for the 
lateral and ventral spinothalamic tracts (Patestas and Gartner, 2006; Gaudio, 2012) 
 The substantia gelatinosa of Rolando - Lamina II, constitute the superficial 
dorsal horn and is characterized by the presence of numerous small neurons. 
Lamina II can be further divided into outer (IIo) and inner (IIi) parts, with IIi 
having a somewhat lower density of neurons. This nucleus extends the entire length 
of the cord and is most prominent in the cervical and lumbar levels. C fibers 
delivering pain, temperature, and light touch information terminate on neurons in 
dorsal horn lamina II. Cells in this lamina also form intersegmental connections. 
Descending fibers from higher centers (such as the cerebral cortex) form excitatory 
and inhibitory synapses with the cells of the substantia gelatinosa, thus modifying 
the incoming pain and temperature sensations (Ralston, 1979; Usunoff et al., 2006; 
Todd, 2010) 
 The nucleus proprius - Laminae III and IV, extends the entire length of the 
spinal cord. It is composed of densely clustered large nerve cell bodies, located just 
ventral to the substantia gelatinosa, and receives the central processes of the 
majority of the DRG neurons. The nucleus proprius receives pain, light touch, and 
temperature sensations and provides input to the lateral and ventral spinothalamic 
tracts (Beal and Cooper, 1978; Usunoff et al., 2006) 
 Lamina V extends across the neck of the dorsal horn and in all but the thoracic 
region is divided into medial and lateral portions. The lateral portion consists of the 
reticular nucleus that is most conspicuous in the cervical neuromeres. The C and 
Aβ nociceptive fibers terminate in this layer. Morevoer, corticospinal synapses 
have been identified in this lamina.  
 Lamina VI is a wide zone most prominent in the cervical and lumbar 
enlargements. At these levels, it is divided into medial and lateral zones. Terminals 
from the posterior roots end in the medial region whereas descending fiber tracts 
project to the lateral zone. 
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Intermediate Region: Lamina VII 
 Lamina VII includes most of the intermediate region of the gray matter in the 
spinal cord. In this lamina are found the intermediolateral and intermediomedial 
nuclei. The nucleus dorsalis, also known as Clarke’s column is located at the base 
of the dorsal gray column and houses relatively large cell bodies that receive 
synapses from proprioceptive fibers, which bring information from Golgi tendon 
organs and muscle spindles. Some of the axons of these large nerve cell bodies 
travel in the dorsal spinocerebellar tracts. Cells in lamina VII form tracts that 
project to higher levels, including the cerebellum and thalamus. In the thoracic and 
sacral regions, this lamina also hosts visceral motor neurons whose axons leave this 
lamina to form preganglionic autonomic connections (Barr and Kiernan, 1983; 
Wall, 1987; Graham et al., 2007). 
To sum up, the A-delta and C fibers enter the spinal cord as the lateral bundle of the dorsal 
root, they bifurcate into branches that ascend and descend one or two spinal levels as 
constituents of the dorsolateral fasciculus of Lissauer, from where they enter and terminate 
on projection neurons in the dorsal horn (Grant, 1995; Jessell and Kelly, 1997) (cfr Fig 3). 
In the gray matter, spatial organization of incoming primary afferent fibers provides that 
myelinated low-threshold mechanoreceptive afferents arborize in an area extending from 
lamina IIi–V, whereas nociceptive and thermoreceptive Aδ and C afferents innervate 
lamina I and much of lamina II, except for its most ventral part. Recent studies have 
identified a group of cooling-specific C afferents that terminate in lamina I, as well as two 
possible candidates for low-threshold mechanoreceptive C fibres that project to lamina II. 
In the gate control theory, small-diameter and large-diameter primary afferents converge 
on “pain transmission neurons” of the “action system”. In particular, all somatic afferents, 
including nociceptors, activate second order “convergent” neurons, namely wide-dynamic-
range (WDR) cells, located in the deep dorsal horn that, travelling in the spino-thalamic 
tract (STT), project to the main somatosensory thalamus and then to the primary 
somatosensory cortex (Wall 1973, Price and Dubner 1977; Price, 1988; Willis, 1985; 
Willis and Westlund 1997)(cfr Fig. 4). The activity of the WDR cells is viewed as 
necessary and sufficient for pain sensation and is characterized as graded throughout the 
range of tactile sensitivity, so that WDR neurons respond with progressively greater levels 
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of discharge to brushing hair, light touch, pressure, pinch, and squeeze (Craig, 2003) (cfr 
Fig 3). 
 
 
Figure 3. Neuronal architecture of the dorsal horn 
Laminae (represented by numerals I-VI) are morphologically and functionally distinct layers within 
the gray matter of the spinal cord. Lamina I primarily contains large projection neurons that send 
processes up the spinal cord towards higher brain regions. Lamina II, in contrast, is more heavily 
populated with interneurons, many of which supply inhibitory signals to lamina I projection 
neurons. Lamina V con‐tains wide dynamic range neurons that receive primary input from multiple 
sensory odalities. Peripheral afferents project to distinct laminae. While Aδ and C fibers are 
associated with superficial laminae, Aβ fibers project more medially (original image from Berger et 
al., 2011). 
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Figure 4. Gate control theory 
The theory is based on the understanding that pain is transmitted by two kinds of afferent nerve fibers. One is 
the larger myelinated A-delta fiber, which carries quick, intense-pain messages. The other is the smaller, 
unmyelinated "C" fiber, which transmits throbbing, chronic pain. A third type of nerve fiber, called A-beta, is 
"nonnociceptive," meaning it does not transmit pain stimuli. In this concept, pain can be modulated by the 
balance of the interactions among the nociceptive C fibers and non-nociceptive A-alpha (proprioception) and 
A-beta afferent (touch) fibers of the peripheral nerves, and the interneurons and projection neurons of the 
dorsal horn. The interneuron, which normally inhibits the projection neuron, is spontaneously active and, 
thus, reduces (inhibits) the intensity of the noxious input from the C fibers. The influences exerted by the 
spontaneous activity of the interneuron on the projection neuron are modulated by excitation from the non-
nociceptive A fibers and inhibition from the nociceptive. 
C fibers. In essence, nociceptive C fibers tend to keep the gate open (enhancing perception of pain) by 
inhibiting the inhibitory interneuron and exciting the projection neuron. The non-nociceptive A fibers tend to 
keep the gate closed (suppression of pain) by exciting the inhibitory interneuron. In addition, the reflected 
feedback descending influences from the brain can modulate the excitability of these neurons (original image 
from http://www.positivehealth.com). 
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1.3. Pain sensory pathways  
 
Transmission of pain through the chain of primary afferent neurons and dorsal horn cells is 
influenced by many factors, some of which originating within the segment, some from 
higher centers. The anterolateral system (ALS) has long been known to be a major 
pathway for the transmission of general somatic protopathic information to the cerebral 
cortex. ALS comprises the spinothalamic tract (STT), the spinomesencephalic tract and the 
spinoreticular tract. Fibers carrying pain and temperature ascend in the contralateral 
spinothalamic tract. Compression, intrinsic disease, or deliberate section of STT result in 
anesthesia of the contralateral body beginning 3 segments below the level of disruption. 
STT shows both somatotopic and functional arrangement, as pain fibers are located 
anteriorly, temperature ones are located posteriorly. Ascending spinothalamic fibers 
terminate in the ventral posterior lateral nucleus and in the intralaminar nuclei (Willis, 
1985, Willis and Westlund, 1997; Craig, 2003; Jacobson and Marcus, 2011) (cfr Fig. 5). 
Only when nociceptive information reaches the thalamus and cerebral cortex, should we 
talk about pain. Pain perception by these higher centers triggers affective responses and 
suffering behaviours. The pain experience depends on the circumstances that may alter the 
response and varies so much from person to person that it has be also defined as "a 
subjective perception with a psychological dimension" (Collins et al., 1960; Hunt and 
Mantyh 2001; Scholz and Woolf 2002; Trafton and Basbaum, 2000).  
At thalamic level, sensory information from the body, limb and back of the head is 
collected by neurons of several thalamic nuclei including the ventral posterolateral (VPL), 
posterior (PTh) and intralaminar nuclei, whereas somatosensory information from the head 
reaches the ventral posteromedial nucleus (VPM).  
As regards the processing of nociceptive information, it seems that the thalamus tells us 
about the quality of information (the "what" component) and the somatosensory cortex 
tells us about the spatial localition of the sensation (the "where" component). The (lateral) 
spinothalamic tract originates from projection neurons of laminae I, V, VI, and VII. That 
terminate primarily in VP and PTh thalamic nuclei. Some collateral branches terminate in 
the brainstem reticular formation. This tract conveys information perceived with an overlay 
of the discriminative aspects associated with various subtleties associated with the 
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sensation of sharp pain and, in addition, with thermal sense. At levels successively higher 
than the spinal cord, new fibers join the tract on its medial aspect; producing a laminated 
somatotopically organized tract where, in the upper spinal cord, pain and temperature 
fibers from the sacral region are located posterolaterally and those from the sacral region 
are located anteromedially. Thalamic neurons then project to somesthesic primary area in 
the telencephalic cortex and this projection provides the discriminative capacity of the 
nociceptive stimulus (Willis, 1985). VP and PTh nuclei receive input from laminae I and V 
via the spinothalamic pathway, conveying signals primarily from nociceptive-specific and 
wide dynamic range neurons (Craig et al., 1999; Dubner and Gold, 1999; Casey and 
Morrow 1983; Gingold et al., 1991; Craig, 2004; Noback et al., 2005).  
Collaterals of the spino-thalamic fibers originating from spinal laminae VI, VII, and VIII, 
activate intralaminar nuclei via the spinoreticulothalamic pathway; conveying information 
from large complex nociceptive fields. The intralaminar thalamic nuclei send information 
to the limbic system, to the somesthesic secondary area and to insula and these connections 
are responsible for the affective and emotional component of pain. The spinoreticular tract 
and the spinomesenchephalic tract carry nociceptive information to midbrain and reticular 
formation. 
The spinomesencephalic tract is composed of the fibers of projection neurons in laminae I 
and Vand terminates in the periaqueductal gray (PAG) of the midbrain; this tract is 
involved in the modulation of pain and in the functioning of the reticular system 
(Reynolds, 1969, Mayer et al., 1971). 
The spinoreticular tract is integrated into the spinoreticulothalamic pathway terminating in 
the intralaminar thalamic nuclei. It originate from neurons in laminae VII and VIII, which 
receive inputs from large, complex, receptive fields in the periphery.  
From the spinal cord, there are also direct projections to the amygdala and hypothalamus. 
This slowly conducting multisynaptic pathway conveys diffuse poorly localized pain from 
both somatic and visceral sources (Noback et al., 2005; Garcia, 2012). 
Finally, the thalamus also receives pain and temperature pathways from receptors in the 
rest of head and scalp via the trigeminothalamic and trigeminoreticulothalamic tracts. 
These fibers convey impulses via the three divisions of the trigeminal nerve (ophthalmic, 
maxillary, and mandibular) and cranial nerves VII, IX, and X. The trigeminothalamic tract 
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is included in the lateral pain system (Patestas and Gartner, 2006; Gaudio, 2012; Noback et 
al., 2005) (cfr Fig. 5). 
 
Figure 5. Schematic representation of the anterolateral system 
First order neurons reside in the DRG and collect sensory information by means of their centrifugal branches 
reaching the periphery. Their centripetal branches enter the spinal cord, ascend 1-2 levels, and terminate in 
the substantia gelatinosa; second order neurones carry the sensory information from there to the thalamus. 
Fibers arising from second order neurons, before entering the spinothalamic tract, decussate and split: those 
carrying crude touch and pressure enter the lateral spinothalamic tract, those carrying pain and temperature 
enter the anterior spinothalamic tract. Although functionally distinct, these tracts run alongside each other, 
and they can be considered as a single pathway. The fibres travel in their respective pathways, synapsing in 
the thalamus. Third order thalamic neurones transfer the sensory signals to the primary sensory cortex. The 
descending pathway is represented by the dashed lines (original image from Firestein, Kelley's Textbook of 
Rheumatology, 8th ed.). 
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1.3.1 Central and peripheral mechanisms of nociceptive processing  
 
The spinal cord actively amplifies the spinal nociceptive processing because nociceptive 
spinal cord neurons change their excitability to inputs from the periphery under painful 
conditions. On the other hand, it has to be reminded that the spinal cord is under the 
influence of descending influences (Schaible, 2007).  
Under normal conditions, the release of excitatory amino acids by afferent fibers induces a 
depolarization of dorsal horn neurons. Glutamate, released during tonic activation of C 
fibers, is the principal excitatory transmitter acting at the synapse between primary afferent 
nociceptors and dorsal horn cells (Alvarez et al., 2010). Glutamatergic receptors on the 
second order sensory neurons are mainly ionotropic, i.e. directly coupled to cation 
channels, which can be further subdivided into AMPA (amino 3-hydroxy-5-methyl-4-
isoxazolepropionic acid)/kainate and NMDA receptors. Glutamate initially binds to AMPA 
receptor that produces a rapid depolarization followed by activation of the NMDA receptor 
(Lovinger, 2008; Latremoliere and Woolf, 2009). 
Excitatory neuropeptides are co-localized with glutamate. Neuropeptide-mediated 
excitatory postsynaptic potentials usually occur after a latency of seconds and are long-
lasting. They may not be sufficient to evoke action potential generation but act 
synergistically with glutamate (Urban et al., 1994) Substance P (SP) is released mainly in 
the superficial dorsal horn by electrical stimulation of unmyelinated fibres and during 
noxious mechanical, thermal or chemical stimulation of the skin and deep tissue (Afrah et 
al., 2002; Khasabov et al., 2002; Ma and Woolf, 1995; Mantyh et al., 1997). Neurokinin-1 
(NK-1) receptors for SP are mainly located on dendrites and cell bodies of dorsal horn 
neurons in laminae I, IV–VI and X (Gauriau and Bernard 2002). Upon strong activation by 
SP, NK-1 receptors are internalized. In addition, neurokinin A (NKA) is found in small 
DRG cells and in the dorsal horn and spinally released upon noxious stimulation. CGRP, 
which is often colocalized with SP in DRG neurons, is released in the spinal cord upon 
electrical stimulation of thin fibres and upon noxious mechanical and thermal stimulation, 
potentiates the effects of SP (by inhibiting its enzymatic degradation and potentiating its 
release). It participates in the phenomenon of central sensitization, i.e. the changes in 
synaptic efficacy between afferent neurons and central neurons that increase the perception 
of pain. Once released by primary afferent terminals, it acts through postsynaptic CGRP 
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receptors, which activate PKA and PKC (Woolf and Wiesenfeld-Hallin, 1976). CGRP 
binding sites are located in lamina I and in the deep dorsal horn. Blockade of CGRP effects 
reduces nociceptive responses (Schaible, 2006).  
Under pathological conditions, the second and third order neurons undergo widespread 
neuronal plasticity and neuronal rewiring to become hyperactive. The result of these 
processes may lead to the transformation of an initially adaptive reactivity in a series of 
counterproductive, often maladaptive responses. Observed changes include modulation of 
synaptic transmission and induction of LTP (Ueda, 2006; Premkumar, 2010). Peripheral 
sensitization involves an increase in the responsiveness of nociceptive ion channels and a 
reduction in activation threshold of nociceptive neurons (Julius and Basbaum, 2009; Woolf 
and Salter, 2008). Sensitization of nociceptive ion channels can result in ectopic or 
spontaneous discharges, alteration in ion channel expression, and increased neuronal 
sprouting (Nordin et al., 1997; Premkumar, 2010). 
  
 Prolonged activation of C fibers by noxious stimuli depolarizes dorsal horn 
neurons and induces direct activation of NMDA receptors. Activation of NMDA 
receptors subsequently allows a massive influx of calcium within the cell, which 
provokes a cascade of intracellular events leading to the long-lasting modification 
of the properties of dorsal horn neurons. These events, including the activation of 
the calcium-dependent protein kinase C (PKC) and of the nitrous oxide (NO) 
synthase, may in turn lead to phosphorylation of the NMDA receptor and thereby 
enhance the calcium current generated by a given glutamate release (Kampa et 
al., 2004; Van Dongen, 2009; Premkumar, 2010)(cfr Fig. 6). 
  
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Figure 6. Nociceptive processing in the spinal cord dorsal horn 
Nociceptive neurons synapse with interneurons, they stimulate nociceptive projection neurons to signal the 
higher centers in the brain.The interneurons that cross the anterior commissure and ascend in the 
contralateral spinothalamic tract transmit pain signals to the lateral thalamus, where they synapse with third-
order neurons that project to the somatosensory and cingulate cortices to produce consciousness of the type 
and location of the tissue injury. Interneurons that inhibit the nociceptive projection neurons are activated by 
incoming sensory afferents and descending tracts that reduce nociceptive processing at the spinal level. 
These pathways originate from the brainstem (periaqueductal gray, nucleus raphe magnus) and descend 
through the dorsolateral funiculus of the spinal cord (original image from www.mdconsult.com). 
 
According to the hypothesis of central sensitization, a large amount of various 
neurotransmitters and neuromodulators are released into the spinal cord by injury 
discharges (cfr Fig. 6), which have been implicated in the initiation of spinal cord circuit 
changes that are responsible for the neuropathic pain (Lee and Kim, 2007). Upon the 
repetitive C-fiber stimulation, the spinal dorsal horn neurons are in a depolarized state as a 
result of prolonged and amplified neuronal responses, which is dependent on NMDA 
receptor activation (Suzuki and Dickenson, 2005; Woolf and Salter, 2000; Premkumar, 
2010). The spinal cord neurons increase their receptor expression and 
neurotransmitter/neuropeptide release. Central sensitization also involves descending 
projections from supraspinal sites that facilitate nociceptive transmission (Urban and 
Gebhart, 1999). In certain conditions, loss of inputs from the periphery may reorganize 
both spinal and supraspinal circuitry, which include glutamatergic, GABAergic, 
glycinergic and neuropeptidergic systems. Among the latter, substance P and CGRP as 
pain-transmitting or pain-modulating peptides are released into the spinal cord from the 
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central terminals of thinly myelinated and unmyelinated primary sensory neurons and are 
involved in central sensitization (Dubin and Patapoutian, 2010).  
 
In addition, nociceptive ion channels contribute to the specificity of primary afferent fibers 
carrying a selective modality of pain. Among these, the identification of the transient 
receptor potential type 1 receptor -TRPV1- was the major catalyst that launched the fields 
of somatosensory and pain transduction research to the molecular level (Stucky et al., 
2009). 
TRPV1 is a non selective cation channel which likely consists of four subunits, with each 
containing 6 transmembrane domains (Voets et al., 2005), it is mainly expressed in 
peptidergic neurons, and to a lesser extent in the non-peptidergic nociceptors, the 
expression also occurs in various other brain regions and in several non-neuronal tissues. 
Particularly TRPV1 is expresed in a subset of small-sized DRG, trigeminal and nodose 
ganglia nociceptive neurons bearing C and Aδ fibers (Caterina et al, 1997; Tominaga et al., 
1998) where mediates sensory perception especially in nociception. (Caterina et al., 1997)  
 
 Physiologically its role is essential for detecting noxious stimuli such as acidic pH 
(Tominaga, 1998), heat (>43 °C) (Caterina et al., 1997), and chemicals including 
capsaicin (Caterina et al., 1997) and anandamide (Zygmunt et al., 1999). TRPV1 
exerts a pronociceptive role acting as a "molecular integrator" due to the 
multimodal sensory stimuli activation (Guo et al., 1999; Caterina et al., 2000) thus 
it is essential in modulation of pain sensation and development of thermal 
hypersensitivity (Caterina et al., 2000; Davis et al., 2000). Also it plays a key role 
in the development of the burning pain sensation associated with acute exposure to 
heat, and with inflammation in peripheral tissues (Valtschanoff et al., 2001) (cfr 
Fig. 7). 
 
TRPV1 activation causes neuronal depolarization and triggers sensory nerve efferent 
function that occurs by the release of neuropeptides, such as bradykinin, CGRP and SP, 
from peripheral and central nerve terminals (Maggi and Meli, 1988; Holzer, 2008). The 
neuropeptides, upon activation of their effector cell receptors, are able to recruit fibers that 
carry light touch resulting in allodynia around the injected area and enhance the 
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sensitization of nociceptors (Holzer, 2008; Szallasi and Blumberg, 2009). Repeated 
activation of the TRPV1 receptor causes the overload of intracellular Ca2+, resulting in 
oxidative stress and apoptotic cell injury (Shin et al., 2003; Kim et al., 2005). For these 
reasons the receptor has also been shown to play a role in certain chronic pain conditions, 
such as neuropathic pain, osteoarthritis, bone cancer pain, inflammatory bowel disease and 
migraine (O'Neill et al., 2012). Chronic pain-induced sensitization also intensifies the 
expression of TRPV1 receptor in sensory neurons through transcriptional and translational 
regulation, post-translational changes and altered trafficking, contributing to the 
development of pathological pain states in which increased sensitivity to noxious stimuli 
occurs (Hucho and Levine, 2007) 
Capsaicin-induced nocifensive behaviour and hyperalgesia in rodents and pain in humans 
are well established (Gilchrist et al., 1996; Simone et al., 1987; Szolcsányi, 1977). 
TRPV1 antagonists have shown efficacy in animal models of both inflammatory and 
neuropathic pain (Patapoutian et al., 2009) but systemic administration of TRPV1 
antagonists commonly results in hyperthermia caused by peripheral TRPV1 blockade 
(Steiner et al., 2007). Activation of spinal TRPV1 can generate central sensitization and 
mechanical allodynia (Patwardhan et al., 2009) and spinal administration of TRPV1 
antagonists can attenuate mechanical allodynia induced by nerve injury (Patapoutian et al., 
2009), but the cell types or circuits underlying these effects are unknown (Kim et al., 
2012).  
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Figure 7. TRPV1 activation 
The TRPV1 channel can be activated by vanilloids such as capsaicin, as well as endogenous stimulators 
including H+, heat, lipoxygenase products and anandamide. TRPV1 channel function is upregulated by 
several endogenous mediators present in inflammatory conditions which decrease the threshold for 
activation of the channel. Under these conditions, TRPV1 can be activated by physiological body 
temperature, slight acidification or lower concentration of TRPV1 agonists. There is evidence that 
TRPV1 plays a role in the development of pathophysiological changes and symptoms in chronic pain 
sensation Activation of TRPV1 by capsaicin results in sensory neuronal depolarization, and can induce 
local sensitization. High concentrations of capsaicin or repeated applications can produce a persistent 
local effect on cutaneous nociceptors, which is best described as defunctionalization and constituted by 
reduced spontaneous activity and a loss of responsiveness to a wide range of sensory stimuli. When 
activated by a combination of heat, acidosis, or endogenous/exogenous agonists, TRPV1 may open 
transiently and initiate depolarization mediated by the influx of sodium and calcium ions. In the 
nociceptive sensory nerves which selectively express TRPV1 (mostly C- and some Aδ-fibres), 
depolarization results in action potentials, which propagate into the spinal cord and brain, and may be 
experienced as warming, burning, stinging, or itching sensations. (original Image from 
http://www.medscape.com). 
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1.4. The importance of animal models of chemotherapy-induced PN  
 
In the past 20 years, several animal models have been published and used to further 
investigate mechanisms of anticancer agent-induced neuropathic pain. Most frequently 
experimental models have been developed in rodents (Authier et al., 2009). Many models 
were not intended to suggest an immediate translation into clinical use, but rather to 
illustrate a concept and to identify a possible novel mechanism that could be exploited to 
avoid this important chemotherapy-induced side effect. Collectively, findings achieved by 
means of animal models add to the complexity and multiplicity of the mechanisms 
underlying the chemotherapy-induced PN. 
Primary afferent nerve fibers affected by chemotherapy-induced neurotoxicity exhibit both 
positively and negatively regulated nociceptive thresholds (Nahman-Averbuch et al., 
2011). As a whole, nociceptive thresholds are increased when there occurs nerve fiber loss, 
whereas are reduced as a result of peripheral and central sensitization (Nahman-Averbuch 
et al., 2011). So, thermal hypoalgesia has been associated to chemotherapy-induced PN in 
both humans (Dougherty et al., 2004; Cata et al., 2006; Attal et al., 2009; Nahman-
Averbuch et al., 2011) and rodent models (Authier et al., 2000, 2003; Fischer et al., 2001; 
Cata et al., 2006, 2008; Garcia et al., 2008; Hori et al., 2010; Xiao et al., 2012; Zheng et 
al., 2012). Cold allodynia, a characteristic symptom of painful chemotherapy-induced PN, 
also occurs in both patients (Cata et al., 2006) and experimental models (Cata et al., 2006; 
Authier et al., 2009; Xiao et al., 2012).  
Variations in nociceptive thresholds are accompanied by neurochemical changes. For 
example, in the DRGs and hindpaw skin of hyperalgesic mice TRPV1 expression levels 
are increased, whereas they decrease in hypoalgesic animals (Pabbidi et al., 2008). 
Conversely, thermal hypoalgesia may be underpinned by reduced TRPV1 expression and 
function (Pabbidi et al., 2008). 
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Aim of the study  
 
The present work is the result of a cooperative study on the bortezomib-induced PN, 
carried out on a rat model of PN induced by the drug chronic administration, that shares 
common neurophysiological, behavioral and pathological features with the sensory 
neuropathy described in humans (Cata et al., 2007; Argyriou et al., 2012). The rat model 
of bortezomib-induced PN has been developed and characterized by the reaserch team of 
prof. Guido Cavaletti, Department of Surgery and Translational Medicine, University of 
Milan-Bicocca, Italy.  
The research has been designed to provide insight on an intrinsic contraddition 
emerging from the previous histopathological characterization of the model. In fact, 
though an evident axonopathy, affecting mainly Adelta and C fibers, can be easily 
detected, no evident changes in DRG neuronal cell body morphology could be observed 
(Cavaletti et al., 2007; Meregalli et al., 2010). Considering those findings, the aim of this 
study was to investigate whether the lack of morphological alterations revealed by 
histopathological analysis could be in line with observations of neurochemical changes 
likely involved in the onset and persistence of nociceptive symptoms caused by 
bortezomib-induced neurotoxicity occurring in DRGs and peripheral nerve fibers. For 
this reason, it was examined whether intravenous bortezomib administration, either as a 
single-dose or on a “chronic” schedule, affects the expression of neurochemical sensory 
markers such TRPV1, CGRP and SP in lumbar DRGs, spinal cord and sciatic nerve by 
means of immunohistochemical, western blot (WB) and reverse transcriptase-polymerase 
chain reaction (RT-PCR) assays. 
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2.Results 
 
2.1 General toxicity 
 
Bortezomib administration at doses of 0.20 mg/kg was well tolerated by rats while in the 
chronic experiment 8 animals treated with bortezomib died within the first 4 weeks of 
treatment. No acute distress was observed in the rats sacrificed 1 hour after bortezomib 
administration. During the first week of treatment only occasionally the animals showed 
mild signs of discomfort such as piloerection, hypokinesia and chromodacryorrhoea; in 
general, animal behavior was otherwise normal and no other remarkable evidence of 
general toxicity was observed. 
Furthermore a not statistically significant weight loss during the first 10 days of 
bortezomib treatment was observed. As shown in Figure 8, the body weight assumed the 
same trend of control rats during the treatment, therefore no significant difference occurs in 
the body weight of control and bortezomib-treated animals. 
 
 
Figure 8. Body weight changes 
Body weight changes throughout the chronic bortezomib-treatment. No evident differences in weight gain vs. 
control (CTRL) are evident during the treatment (mean values ± SD). 
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2.2 Neurotoxicity and pain assessment 
 
2.2.1 Mechanical nociceptive threshold 
 
Bortezomib-treatment induced changes in mechanical nociceptive threshold as evaluated 
by means of the Dynamic Aesthesiometer test. The mechanical threshold was measured 
before starting the pharmacological treatment (baseline value) and after 8 weeks of chronic 
treatment (mean values ± SD, n = 12 in each group during the treatment period). Figure 9 
shows that no significant difference in the mean withdrawal response at baseline occurs. At 
the end of the bortezomib-treatment, the mechanical paw-withdrawal threshold 
significantly decreased in the treated animals compared to the control ones. 
 
 
 
Figure 9. Dynamic Aesthesiometer test 
Bortezomib-induced changes in Dynamic Aesthesiometer test.  
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2.3 Immunohistochemistry 
 
Tissue sections were processed for immunohistochemistry for both ABC method and 
immunofluorescence to ascertain possible neurochemical changes in TRPV1 receptor and 
the neuropeptides SP and CGRP, likely involved in neuropathic pain transmission. 
 
2.3.1 Dorsal Root Ganglia 
 
The immunostaining for TRPV1-, CGRP- and SP-like protein in the DRG was intense in a 
subpopulation of small neurons, whereas a more moderate level of staining was observed 
in other small and medium neurons (cfr Fig 10, 11). 
 
 
Figure 10. Bortezomib acute treatment 
Immunoreactivity to TRPV1 (A, B), CGRP (C, D) and SP (E-F-G) in representative sections of lumbar DRG 
from control (ctrl) (A, C, E) and Acute bortezomib-treated rats (B, D, F, G). Scale bars = 25 μm. 
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Figure 11. Bortezomib chronic treatment 
Immunoreactivity to TRPV1 (A, B), CGRP (C, D) and SP (E-F) in representative sections of lumbar DRG 
from control (ctrl) (A, C, E) and chronically bortezomib-treated rats (B, D, F). Scale bars = 25 μm. 
 
TRPV1-, CGRP- and SP-like immunoreactive (LI) neurons were fairly heterogeneous in 
both the density of reaction product and the cell size after acute (cfr Fig. 10) and chronic 
(cfr Fig. 11) bortezomib treatment. The immunolabeling had a granular appearance and it 
was distributed throughout the cytoplasm. Uneven positive staining, suggestive of a 
discrete localization in the Golgi apparatus and Nissl substance, could be seen in a number 
of immunostained neurons. TRPV1-, CGRP- and SP-LI nerve fibers were also present 
between neuronal cell bodies and in nerve bundles. 
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2.3.2 Morphometry 
 
After acute treatment the proportion of DRG labeled neurons increased by about 3 % (p < 
0.005) for TRPV1 and about 10% for CGRP (p < 0.001), whereas it did not change for SP 
(cfr Fig. 12, top). In some specimens, peripheral neuronal SP-like immunoreactivity 
suggestive of labeled satellite cells was observed (cfr Fig. 10). 
After chronic bortezomib-treatment the proportion of TRPV1-LI neurons significantly 
increased by about 11% (p < 0.001) and that of CGRP-LI neurons by about 5% (p < 
0.001), whereas it did not change for the SP-LI neuronal subpopulation (cfr Fig.12, 
bottom). 
Size frequency histograms of labeled neurons in acutely and chronically treated rat DRGs 
shows the mean cell diameter of TRPV1-, CGRP- and SP-LI DRG neurons ranged from 8 
to 55 μm in acutely treated rats, and from 10 to 65 μm in chronically treated animals. The 
majority of measured neurons were in the range of small (diameter < 25 μm) and medium 
(25-35 μm)-sized cells, with a mean cell diameter between 15 μm and 30 μm. Moreover, 
for all markers, a statistically significant rearrangement in the size distribution of positive 
neurons was observed in both acutely and chronically treated rats, with differential changes 
involving the relative frequency of small- and medium-sized immunoreactive neurons. In 
particular, after acute treatment, the TRPV1-, CGRP- and SP-LI neurons with a mean 
diameter of 5-20 μm decreased, whereas those with a mean diameter > 25 μm increased in 
number. After chronic treatment, TRPV1-LI small (15-25 μm) and medium-large neurons 
(35-60 μm) slightly increased; whereas, the number of stained neurons with a mean cell 
diameter of 25-30 μm decreased. CGRP-LI neurons with a mean cell diameter of 10-25 μm 
decreased, while those between 25 and 55 μm increased.A slight, but non-significant 
increase occurred in the SP-LI neurons with a mean cell diameter of 10-20 μm (p = 0.058). 
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Figure 12. Percentage relative frequency  
Size frequency histogram of TRPV1-, CGRP-, and SP-LI DRG eurons from control (ctrl) and acute bortezomib-treated 
rats (on top) and from control (ctrl) and chronic bortezomib-treated rats (on bottom). Cells present in at least 6 sections 
were measured. X-axis values represent the mean cell diameters expressed in μm; y-axis reports values of relative percent 
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frequency. Curve superimposed on the histogram represents the theoretical normal distribution. N = total number of sized 
positive neurons; S.D. = standard deviation. 
 
Table 2. Percentage (± confidence limits) of TRPV1-, CGRP- 
and SP-LI DRG neurons in BTZ-treated rats 
 
Acute BTZ-treatment 
ctrl BTZ 
TRPV1 26.86 ± 0.01% 29.55 ± 0.01% 
CGRP 25.32 ± 0.01% 34.89 ± 0.01% 
SP 15.86 ± 0.04% 14.73 ± 0.03% 
 
Chronic BTZ-treatment 
ctrl BTZ 
TRPV1 28.65± 0.02% 39.93 ± 0.03% 
CGRP 28.59± 0.02% 34.87± 0.02% 
SP 20.60± 0.01% 19.85± 0.01% 
 
 
2.3.3 Immuno-colocalization 
 
The analysis of double immunofluorescence-stained tissue for TRPV1 and either 
neuropeptide revealed that the neuronal co-expression of TRPV1/SP and TRPV1/CGRP is 
partial, occurring in approximately 45% of TRPV1-LI neurons in control animals. An 
estimation of changes in TRPV1/either neuropeptide co-expressing neurons suggested that, 
in the acute treated group (cfr Fig. 13), the TRPV1/CGRP subpopulation did not show any 
statistically significant change, whereas the TRPV1/SP one decreased significantly (-12%, 
p < 0.05; Table 1). In the chronic treated group (cfr Fig. 14), both TRPV1/CGRP- (-7%; p 
< 0.05) and TRPV1/SP-coexpressing neurons (-8%, p < 0.005) showed a statistically 
significant decrease (Table 3). 
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Figure 13 Bortezomib acute treatment 
Double labeling immunofluorescence for TRPV1/CGRP (A-C, D-F) and TRPV1/SP (G-I, J-L) in DRG 
neurons from control (ctrl) ( A-C, G-I) and acutely bortezomib-treated rats ( D-F, J-L) C, F, I, L represent the 
composite images obtained by overlay of A-B, D-F, G-I and J-L, respectively. Scale bar = 25 μm. 
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Figure 14. Bortezomib chronic treatment. 
Double labeling immunofluorescence for TRPV1/CGRP (A-C, D-F) and TRPV1/SP (G-I, J-L) in DRG 
neurons from control (ctrl) (A, D, G, J) and chronically bortezomib-treated rats (B, E, H, K). C, F, I, L 
represent the composite images obtained by overlay of A-B, D-E, G-H and J-K, respectively. Scale bar = 25 
μm. 
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Acute bortezomib-treatment 
Ctrl Bortezomib 
TRPV1/CGRP 
43.68 ± 0.06% 
(58 colocalized/87 TRPV1) 
TRPV1/CGRP 
49.43 ± 0.11% 
(43 colocalized/87 TRPV1) 
CGRP/TRPV1 
39.58 ± 0,10% 
(58 colocalized/96 CGRP) 
CGRP/TRPV1 
41.35 ± 0.01% 
(38 colocalized/104 CGRP) 
TRPV1/SP 
43.53 ± 0.11% 
(37 colocalized/85 TRPV1) 
TRPV1/SP 
32.33 ± 0.06 %* 
(86 colocalized/266 TRPV1) 
SP/TRPV1 
35.92 ± 0.1% 
(37 colocalized/103 SP) 
SP/TRPV1  
44.10 ± 0.07%** 
(86 cocalized/195 SP) 
 
Table 3 
Percentage (± confidence limits) of TRPV1/neuropeptide DRG neurons in bortezomib-treated rats.P value of 
ctrl rat vs bortezomib-treated rat colocalization degree: * p 0.05, ** p = 0.090. 
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Chronic bortezomib-treatment 
ctrl bortezomib 
TRPV1/CGRP 
43.86 ± 0.092% 
(50 colocalized/114 TRPV1) 
TRPV1/CGRP 
36.84 ± 0.11% 
(28 colocalized/76 TRPV1) 
CGRP/TRPV1 
36.76 ± 0.003% 
(50 colocalized/136 CGRP) 
CGRP/TRPV1 
27.72 ± 0.09% * 
(28 colocalized/101 CGRP) 
TRPV1/SP 
43.33 ± 0.1% 
(39 colocalized/90 TRPV1) 
TRPV1/SP 
24.81 ± 0.07% ** 
(33 colocalized/133 TRPV1) 
SP/TRPV1 
50.00 ± 0.006% 
(39 colocalized/78 SP) 
SP/TRPV1 
61.11 ± 0.13% 
(33 cocalized/54 SP) 
 
Table 4 
Percentage (± confidence limits) of TRPV1/neuropeptide DRG neurons in bortezomib-treated rats. p value of 
ctrl rat vs bortezomib-treated rat colocalization degree: *p=0.072; ** p=0.0016 
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2.3.4 Spinal cord 
 
The majority of immunoreactivity to TRPV1, CGRP and SP was found in the dorsal horn 
both in acute (cfr Fig. 15) and chronic (cfr Fig. 16) bortezomib treated rats.  
 
Figure 15. Bortezomib acute treatment 
Immunoreactivity to TRPV1 (A, B, C), CGRP (D, E, F) and SP (G, H, I) in representative sections of lumbar 
spinal cord dorsal horn from control (ctrl) (A, D, G) and chronically bortezomib-treated rats (B, E, H). Scale 
bar = 100 μm. 
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Figure 16. Bortezomib chronic treatment 
Immunoreactivity to TRPV1 (A, B, C), CGRP (D, E, F) and SP (G, H, I) in representative sections of lumbar 
spinal cord dorsal horn from control (ctrl) (A, D, G) and chronically bortezomib-treated rats (B, E, H). Scale 
bar = 100 μm. 
 
As can be appreciate from the figures 15 and 16 TRPV1-LI structures were prominent in 
Lissauer’s tract and lamina I and occurred with a lighter labeling in inner lamina II. CGRP- 
and SP-LI structures showed a wider distribution, being present in Lissauer’s tract, laminae 
I-III and lamina V. No changes were found in the ventral horn, where CGRP 
immunolabeled motoneurons were detectable. 
 
2.3.5 Image densitometry 
 
Image densitometric analysis of dorsal horn labeling showed a statistically significant 
increase in CGRP immunostaining in the acutely treated animals (p < 0.05) (cfr Fig. 15 F) 
and a trend to increase in chronically treated ones (p = 0.057) (cfr Fig. 16 C, F, I). 
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2.3.6 Sciatic nerve 
 
TRPV1-, CGRP and SP-LI nerve fibers were easily detectable in longitudinal sections of 
sciatic nerves. The results show in the pictures releaved apparent differences between 
treated and control animals were found in both acute (cfr Fig.17) and chronic (cfr Fig 18) 
treated rats. 
 
Figure 17. Longitudinal sections of sciatic nerves of acute bortezomib treated rats 
Double labeling immunofluorescence for TRPV1/CGRP in sciatic nerve from control (ctrl) (A-C) and acute 
bortezomib-treated rats (D-F). C, F represent the composite images obtained by overlay of A-B and D-E, 
respectively. Scale bar = 10 μm. 
 
 
Figure 18. Longitudinal sections of sciatic nerves of chronic bortezomib treated rats. 
Double labeling immunofluorescence for TRPV1/CGRP in sciatic nerve from control (ctrl) (A-C) and 
chronically bortezomib-treated rats (D-F). C, F represent the composite images obtained by overlay of A-B 
and D-E, respectively. Scale bar = 10 μm. 
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Analysis of colocalization performed on double immunofluorescence preparations for 
TRPV1 and CGRP revealed that, in both acutely (cfr Fig. 17) and chronically treated 
animals (cfr Fig. 18), TRPV1-like immunoreactivity occurred mainly in fibers that did not 
show CGRP labeling. Due to the paucity of double-labeled structures, no quantitative 
evaluation was performed.  
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2.4 Western blot 
 
The western blot was performed only for TRPV1 on homogenate of total protein, we did 
not have suitable equipment to recognize CGRP and SP due to their low molecular weight. 
 
Figure 19. Western blot analysis for acute and chronic bortezomib treated rats 
Western blot analysis of TRPV1 in DRG (A, E) and spinal cord (C, G) of acutely and chronically 
bortezomib-treated rats. B, D, F, H: Relative levels of TRPV1 expression in DRG and spinal cord with 
densitometric analysis of the grey levels expressed as a percentage of the optical density (O.D.) ratio of the 
TRPV1-positive bands to the GAPDH-positive ones. Ctrl = control rats. Error bars represent standard 
deviation. Letters “a” and “b” denote significant differences (p < 0.05). 
 
The antibody against TRPV1 labeled a single protein band at the expected mw of 88.9 kDa 
(cfr Fig. 19) in DRGs and spinal cord tissue homogenates. In both acute and chronic 
bortezomib treated rats, TRPV1 protein levels were higher than in control animals. After 
acute treatment, relative optical density (O.D.) of TRPV1 protein bands increased threefold 
in DRG homogenates (cfr Fig. 19 A, B) (p < 0.05) and a mild but not significant increase 
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of TRPV1 protein was also evident in the spinal cord (cfr Fig. 19 C, D). Chronic 
bortezomib-treatment produced a statistically significant increase in the relative O.D. of 
the TRPV1 protein band in both DRGs (cfr Fig. 19 E, F) and spinal cord (cfr Fig. 19 G, H), 
amounting to 75% (p < 0.05) and 100% (p < 0.05), respectively, in bortezomib-treated 
versus control animals. 
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2.5 TRPV1- and CGRP mRNAs  
 
Comparative RT-PCR was performed amplifying the mRNA by means of specific primers 
for TRPV1 and CGRP in acute and chronic bortezomib treated rats. 
 
Figure 20. Comparative PCR analysis for acute and chronic bortezomib treated rats 
RT-PCR analysis of TRPV1 and CGRP mRNAs in DRG (A, C, I, K) and spinal cord (E, G, M, O) of acutely 
and chronically bortezomib-treated rats. B, D, F, H, J, L, N, P: Relative levels of TRPV1 and CGRP 
expression with densitometric analysis of the grey levels expressed as a percentage of the optical density 
(O.D.) ratio of the TRPV1- and CGRP-positive bands to the relevant GAPDH-positive ones. Ctrl = control 
rats. Error bars represent standard deviation. Letters “a” and “b” denote significant differences between 
relative mRNA levels in ctrl versus bortezomib-treated rats (B: p < 0.001; DH: p < 0.05), while letter “a” 
alone denotes non-significant differences. 
 
After acute bortezomib-treatment, no significant changes in the relative O.D. of TRPV1 
mRNA bands occurred in the DRGs (cfr Fig. 20 A, B) and spinal cord (cfr Fig. 20 E, F). In 
addition, relative O.D. of CGRP mRNA bands were unaltered in the DRGs (cfr Fig. 20 C, 
D) and spinal cord (cfr Fig. 20 G, H). After chronic bortezomib-treatment, a significant 
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decrease of the relative O.D. of TRPV1 mRNA band occurred in the DRGs (-50%, p < 
0.001; cfr Fig. 20 I, J), but not in the spinal cord (cfr Fig. 20 M, N), while a significant 
decrease of the relative O.D. of CGRP mRNA band occurred in the DRGs (- 28%, p < 
0.05; cfr Fig. 20 K, L) as well as in the spinal cord (-26%; p < 0.05; cfr Fig. 20 O, P). 
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3. Discussion  
 
The identification of the key effectors of the bortezomib cytotoxicity as well as of the 
molecular factors able to contrast or inhibit its action has been hampered, so far, by the fact 
that the proteasome controls the half-life of the vast majority of cellular proteins 
(Jesenberger and Jentsch, 2004; Adams, 2004). Morevoer, it has been suggested that the 
bortezomib molecule per se, compared to other proteasome inhibitors, could be responsible 
of a neurotoxic effect, because it induces an hyperaccumulation of not degraded 
ubiquitinated proteins (Fernandez et al.,2006). It has been inferred that bortezomib acts 
downstream of proteasome inhibition by interfering with stress kinases, survival signals 
and/or apoptotic factors (Mitsiades et al., 2002). The dysregulation of mitochondrial 
functions and release of reactive oxygen species (ROS) are also common processes 
induced by bortezomib (Liu et al., 2003; Jesenberger and Jentsch, 2004; Adams, 2004). 
Thus, as early as 3–4 h after bortezomib treatment, epithelial tumor cells show a 
dysregulated mitochondrial membrane potential and accumulate ROS, that subsequently 
lead to caspase activation (Ling et al., 2003; Fribley et al., 2004). 
In this scenario, the present study investigated the effects of bortezomib-treatment given 
either as a single acute or a chronic schedule on the neurochemical features of DRG 
primary afferent neurons and their relevant peripheral and central processes. Our results, in 
agreement with previous observations (Meregalli, 2010), show that prolonged bortezomib 
administration induces a PN without appreciable adverse effects on the general condition 
of the animals. 
As expected based on previous observations (Meregalli et al., 2010; 2012), the 
histopathological analysis carried out by colleagues at the University of Milan-Bicocca 
revealed that acute bortezomib-treatment did not induce morphological alterations neither 
in the sciatic nerve nor in the DRG neuronal perikarya. Histopathological analyssi further 
confirmed that, in chronically treated animals, the sciatic nerve showed a mild axonopathy, 
affecting mostly the small myelinated and unmyelinated fibers. Similarly, clear 
cytoplasmic vacuolization was detected in some DRG satellite cells. No obvious changes 
were observed in the dorsal horn of the spinal cord (data not shown). 
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3.1 Neurophysiological evaluation 
 
Neurophysiological and neuropathological assessments were consistent with measures 
at baseline and end of treatment time points previously observed (Meregalli et al., 
2010; 2012). As regards the modification of nocifensive behavior, the chronic model of 
bortezomib-induced PN was associated with the onset of mechanical allodynia as assessed 
after the 8-week treatment. Interestingly, data concerning the weekly outcome of 
bortezomib-treatment showed a significant reduction in withdrawal latency after 4 weeks 
of treatment; however, at the later time point of 8-weeks (end of treatment period) and the 
follow-up 4-week period, the difference was no longer significant (Meregalli et al., 
2010).  
Although the bortezomib schedule used in this study differs from that used in clinical 
practice with respect to the duration of administration and dosage, calculations to 
translate drug doses from animal to human studies (Reagan-Shaw et al., 2008) indicate 
that our model of bortezomib-induced neurotoxicity is highly relevant. In fact, it 
closely mimics the sensory neuropathy described in human patients by sharing with it 
common neurophysiological, behavioral and pathological features, occurring often 
within the ﬁrst cycle of treatment (Cata et al., 2007; Argyriou et al., 2008). 
 
3.2 Bortezomib-induced effects on expression of TRPV1 and CGRP 
mRNAs and proteins 
 
Our results provide novel evidence that bortezomib-induced nocifensive behavior is 
accompanied by increased TRPV1 protein levels in DRGs and spinal cord and down-
regulated levels of TRPV1 mRNA. Decreased levels of CGRP mRNA were also observed 
in both DRGs and spinal cord. 
We do not have a clear-cut explanation of the mismatch between levels of TRPV1 mRNA 
and protein and details about neuronal mechanisms underlying protein/mRNA reciprocal 
changes in this context remain to be elucidated. However, the ubiquitin-proteasome system 
has a role in receptor protein catabolism; as an example, NMDA receptor subunits have 
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been shown to be degraded by the proteasome following ubiquitination initiated by several 
ligases (Kato et al., 2005). Interestingly, novel evidence has been provided that also 
TRPV1 receptor is susceptible to proteasomal degradation, unless it translocates to the 
plasma membrane; in fact, blocking TRPV1 trafficking to the plasma membrane markedly 
decreases total TRPV1 expression due to proteasomal degradation (Shimizu et al., 2012). 
Proteasome-regulated TRPV1turnover appears to be dynamic and has been suggested to be 
related to the fine-tuning of nociception (Kato et al., 2005). In bortezomib-induced NP 
models, the occurrence of axonal degeneration and Schwann cell endosomal membrane 
dilations likely accounts for impaired protein membrane trafficking (Cavaletti et al., 1992; 
Shin et al., 2012; Bruna et al., 2010). In our specimens, the enduring bortezomib-induced 
proteasome inhibition might have well caused a TRPV1 accumulation in the cytoplasm 
which therefore can account for the increased levels of TRPV1 in DRGs.  
As for the observed decrease of TRPV1 and CGRP mRNA relative levels, it has to be 
highlighted that proteasome blockade causes reduction of transcriptional activity and 
nuclear retention of poly(A)RNAs (Voorhees et al., 2003; Cata et al., 2007; Casafont et al., 
2010), though the increase in protein expression itself may act as a retrograde signal to 
modulate transcription. Yet, NF-B proteasome-independent activation pathways have 
also been reported (Mühlen et al., 2001; Pearson et al., 2011) and, depending on the 
targeted cell type, bortezomib may activate rather than inhibit the NF-B canonic 
pathway  
Plasticity of TRPV1 expression in chronic pain conditions is considered to represent 
one of the mechanisms involved in hyperalgesia (Hideshima et al., 2009). The 
functional characterization of TRPV1-labeled neurons goes beyond the aim of this 
study. However, available experimental studies on the systemic administration of 
different TRPV1 antagonists demonstrate a reduction of mechanical allodynia and 
hyperalgesia in animal models of neuropathic, inflammatory and postoperative pain and 
suggest a role of TRPV1 in the modulation of mechanical hyperalgesia (Pomonis et al., 
2003; McGaraughty et al., 2008; Yu et al., 2008)  
Regarding the specific time profile and turnover of TRPV1 protein after the acute 
bortezomib delivery, we were not able to find literature data with which to compare our 
results, since experimental studies on the effect of a bortezomib single dose, both in rats 
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(Casafont et al., 2010) and mice (Trevisan et al., 2013) were not designed to investigate 
the immediate neurotoxicity of its administration. However, pharmacokinetics of 
bortezomib are well known because the drug has been shown to be rapidly distributed into 
tissues after administration of a single dose, with an initial plasma distribution half-life of 
less than 10 minutes. Maximum proteasome inhibition occurs within 1 hour and recovers 
close to baseline within 72 to 96 hours after administration (Schwartz and Davidson, 
2004). Recently, in the same rat model of bortezomib-induced PN as ours and with the 
same dose used in this study, Meregalli et al. (2014) found that a maximal time-dependent 
proteasome inhibition can be observed in peripheral blood mononuclear cells and sciatic 
nerve specimens asearly as 1 hour after a single dose bortezomib delivery, thus supporting 
the possibility of a quick cytoplasmic accumulation of TRPV1 protein, as also suggested 
by the low but significant increase of the proportion of TRPV1-LI neurons in the DRG 
(present data). 
3.3 Bortezomib-induced effects on primary afferent neuron 
histochemical features  
 
Bortezomib-treatment also induced an augmented immunoreactivity to TRPV1 and CGRP 
in the DRG neurons and spinal dorsal horn, and caused a decrease of 
TRPV1/neuropeptide colocalization in DRG neurons. No bortezomib-dependent 
changes were observed for SP immunohistochemical detectability. In some specimens, 
peripheral neuronal SP-like immunoreactivity suggestive of labeled satellite cells was 
observed giving a neurochemical support to our histopathological assessment (see above). 
They further suggest that the histological alterations, already visible after a single acute 
dose of bortezomib and previously reported also for paclitaxel (Authier et al., 2000), are an 
early trait of chemotherapy-induced PN. In addition the preponderance of experimental 
evidence and theoretical considerations, support the notion that changes in satellite glial 
cells, alone or in concert with changes in neuronal function, do affect nociception (Ohara et 
al., 2009).  
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3.4 Percent frequency of labeled DRG neurons 
 
To our knowledge this is the first study reporting that bortezomib treatment in a rat 
model causes a general increase in the percent frequency of TRPV1- and CGRP-LI 
DRG neurons after both acute and chronic administration. Our immunohistochemical 
data are in keeping with those on CGRP-LI neuronal frequency in mouse DRGs after 
chronic bortezomib-treatment (Bruna et al., 2010). The increase in TRPV1- and CGRP-
LI in the DRGs occurs with a parallel increase in the spinal cord dorsal horn. 
Interestingly, increased immunoreactivity for TRPV1 (Yu et al., 2008; Hudson et al., 
2005; Kim et al., 2008) and CGRP (Zheng et al., 2008) has been previously shown in 
uninjured primary afferent neuronal perikarya in different models of nerve lesion. 
Moreover, CGRP expression may increase in several pathological conditions, including 
partial nerve injury, where pain hypersensitivity occurs (Menard et al., 1996.). In 
comparison, cisplatin has been previously reported not alter the DRG expression of SP 
(Apfel et al., 1992)  
 
3.5 Relative size frequency of labeled DRG neurons 
 
In our model, bortezomib administration induced a rearrangement in the relative size 
frequency of TRPV1-, CGRP- and SP-LI neuronal subgroups, suggesting the 
possibility of a drug-induced neuronal phenotype switch that may go with the onset of 
bortezomib-induced mechanical hyperalgesia. These observations are in agreement 
with those obtained in the mouse model of bortezomib neurotoxicity where medium-
sized neurons slightly decrease, small neurons increase and the relative number of large 
CGRP-LI neurons increases (Bruna et al., 2010). Taken together, these data suggest 
that the phenotypic switch secondary to bortezomib-treatment may partly represent the 
neuronal response to treatment, as also suggested by Bruna et al. (Bruna et al., 2010). 
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3.6 TRPV1/neuropeptide colocalization  
 
Overall, the colocalization data support that a portion of the TRPV1-LI DRG neurons are 
neuropeptidergic. The analysis of changes in neuronal colocalization of TRPV1 with 
neuropeptides provides a morphological basis to suggest a role for TRPV1 in the release of 
these molecules and thus in nociceptor sensitization, and supports the possible implication 
of TRPV1-, CGRP- and SP-positive neurons in the persistence of painful neuropathic 
symptoms (Holzer, 2007). The fact that the TRPV1/neuropeptide colocalization seen in the 
DRGs did not parallel that observed in both central and peripheral nerve processes of 
primary afferent neurons is in keeping with previous observations by Guo et al.(1999), 
who suggested alternative mechanisms of neuropeptide release in response to capsaicin 
application. Future studies will examine how these neurochemical changes affect 
neurophysiological function in DRG neurons and the spinal dorsal horn.  
 
3.7 Bortezomib-induced effects on spinal cord histochemical features  
 
The neuronal response to bortezomib neurotoxicity involves not only the DRGs but 
extends to the spinal cord dorsal horn, where neurochemical alterations parallel those 
observed in the periphery. In particular, following bortezomib treatment, densit ies of 
dorsal horn immunolabelling for TRPV1 and CGRP were increased. Importantly, this 
response is larger in the chronically bortezomib-treated animals.  
The basal expression of TRPV1 mRNA in the spinal cord is in keeping with previous 
RT-PCR studies (Sanchez et al., 2001; Kim et al, 2012) and with the recent 
demonstration that TRPV1 expression occurs in GABAergic interneurons of the rat 
dorsal horn, where it mediates neuropathic mechanical allodynia and disinhibits 
nociceptive circuits in the spinal cord (Doly et al., 2004). Interestingly, TRPV1 
expression by glial cells has also been described (Chen et al., 2010) and TRPV1 has 
been reported to be involved in activating spinal glia in mice with nociceptive and 
pathological pain. Moreover, since bidirectional axonal transport of TRPV1 mRNA 
along primary afferents has been demonstrated in some pathological conditions such as 
experimental acute inflammation (Barajon et al., 1996), it cannot be excluded that part 
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of the TRPV1 mRNA detected in our specimens has a primary afferent origin. If this 
was the case, the reduction of TRPV1 mRNA secondary to bortezomib administration 
might be explained by the reduction of its production, and hence by the reduction of 
centripetal transport, by DRG neurons.  
Consistent with changes in TRPV1 transcript and protein levels, CGRP mRNA also 
showed a decrease that may be correlated to the increase in density of CGRP-
immunoreactive structures in the bortezomib-treated versus control rats.  
 
3.8 Comparison with neurochemical phenotype changes observed in 
other chemotherapy-induced PN 
 
While experimental evidence regarding the effects of bortezomib on the neurochemical 
phenotype is limited to data on CGRP and TRP receptors in mouse models, after acute 
(Trevisan et al., 2013) and chronic administration (Bruna et al., 2010; Trevisan et al., 
2013), several studies of sensory neuropeptides (Verdú, et al., 1999; Alessandri-Haber et 
al., 2008) and TRP receptors in the spinal cord and DRG (Ta et al., 2010; Hudson et 
al., 2005) following treatment with different classes of antineoplastic drugs are 
available in rodents. It has been demonstrated for instance that platinum-based 
compounds, taxanes and vinca alkaloids modulate the expression of TRPV1, as well as 
other TRP receptors, in DRG neurons in vitro and in vivo (Zhao et al., 2012; Hudson et al., 
2005). Cisplatin and oxaliplatin affect the expression of TRPV1 and TRPA1 mRNA by 
causing a 3 fold mRNA increase as early as 6 hours after treatment in cultured DRG 
neurons (Zhao et al., 2012). Similarly, trigeminal ganglia (TG) of cisplatin-treated mice 
had significant increases in TRPV1 mRNA expression (Zhao et al., 2012). However, 
mRNA changes are not mirrored by immunohistochemistry studies, showing that no 
change occurred in the proportion of the TRPV1 immunopositive TG neurons in cisplatin- 
and oxaliplatin-treated mice compared to naïve animals (Zhao et al., 2012). In the same 
way, TRP receptors have been shown to have a role in the pathogenesis of paclitaxel-
associated pain symptoms that were related to increased TRPV1 mRNA and protein 
expression in rat DRG neurons (Hudson et al., 2005). A single injection of paclitaxel is 
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sufficient to increase the expression of TRPV1 mRNA and protein in rat DRG (as seen in 
both homogenates and tissue sections by RT-PCR, in situ hybridization and 
immunochemistry), and to enhance TRPV1 expression in the paw skin at day 14 after 
treatment (Hudson et al., 2005). By contrast, the development of sensory disorders 
following vincristine treatment has been related to changes in the expression of 
TRPV4 (Zhao et al., 2012).  
 
Conclusions 
 
 Our data support the notion that bortezomib treatment selectively affects primary 
sensory neurons that for their anatomical and neurochemical characteristics are 
likely involved in the processing of painful sensory stimuli.  
 In DRG neurons and the spinal cord, the bortezomib-induced neurochemical 
changes appeared after a single dose of the drug and were enhanced after chronic 
treatment.  
 Taken together, these findings increase our understanding of the nociceptive 
symptoms associated with bortezomib-induced sensory neuropathy and may 
contribute to the development of new targeted therapies.  
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4.Materials and methods 
 
4.1 Animals and animal care  
 
Animals. A total of 80 adult female Wistar rats (Harlan Italy, Correzzana, Italy), weighing 
175–200 g at the beginning of the experiment, were used for the study. Animals were 
housed in a limited access animal facility with controlled room temperature (22 ± 2°C) and 
relative humidity (55 ± 10%) and under an artificial 12h light/dark cycle (light 7 a.m.–7 
p.m.). The care and husbandry of the animals were in conformity with the institutional 
guidelines in compliance with national (D.L. n.116, Gazzetta Ufficiale della Repubblica 
Italiana, Additional40, Feb 18, 1992 and subsequent modifications) and international laws 
and policies (EEC Council Directive 86/609, OJ L 358, 1, Dec.12, 1987; Guide for the 
Care and Use of Laboratory Animals, US National Research Council, 8th ed., 2011). The 
experimental plan was examined and approved by the Ethics Committee of the University 
of Milan Bicocca.  
 
4.1.1 Drug administration 
 
Bortezomib (LC Laboratories, Woburn, MA) was dissolved in 5% Tween 80, 5% ethanol, 
90% sterile saline. Animals were divided into two experimental groups. One group of 40 
rats was treated with bortezomib by tail vein injection. Eighteen animals received 0.20 
mg/kg of bortezomib as single dose for “acute” schedule and 22 animals underwent an 8-
week period of bortezomib administration for “chronic” schedule, 0.20 mg/kg/day three 
times per week. The remaining 40 animals were left untreated and used as controls for the 
2 time points of examination. Euthanasia for tissue harvesting was done under deep 
xylazine/ketamine anesthesia 1 hour after the single bortezomib dose in the “acute” 
experimental schedule and one day after the last bortezomib administration in the 
“chronic” experimental schedule. 
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4.1.2 General toxicity 
 
The general condition of treated animals was assessed daily and body weight of the 
chronically treated rats was measured twice/week to monitor drug toxicity and for drug 
dose calculation. Animals with evident distress or remarkable weight loss were carefully 
examined by a certified veterinarian experienced with in vivo studies for possible 
withdrawal from the study for humane reasons. 
 
4.2 Neurotoxicity and pain assessment 
 
4.2.1 Mechanical nociceptive threshold 
 
The mechanical nociceptive threshold was assessed using a Dynamic Aesthesiometer Test 
(model 37450, Ugo Basile Biological Instruments, Comerio, Italy), which generated a 
linearly increasing mechanical force. Rats were habituated to the full procedure for 30 
min/day on two consecutive days and testing was conducted on the third day. On each day 
of testing, animals were placed in a Plexiglas chamber (28 x 40 x 35-cm, wire mesh floor) 
in the dynamic aesthesiometer for a 15 min acclimatization period followed by testing. At 
each time point, after the acclimatization period, a servo-controlled mechanical stimulus (a 
pointed metallic filament, 0.5mm diameter) was applied to the plantar surface of the hind 
paw, which exerted a progressively increasing punctuate pressure, reaching up to 50g 
within 20 sec. The pressure evoking a clear voluntary hind-paw withdrawal response was 
recorded automatically and taken as representing the mechanical nociceptive threshold 
index. The mechanical threshold was always assessed alternatively on each side every 2 
min on 3 occasions to yield a mean value. The results represent the maximal pressure 
(expressed in grams) tolerated by the animals. There was an upper limit cut-off of 30 sec 
after which the mechanical stimulus was automatically terminated. If paw movement 
subsequent to stimulus initiation appeared to be related to grooming or locomotion, that 
trial was repeated after a lapse of 1 min. 
  
69 
 
4.3 Sampling 
 
Immediately after sacrifice, the L4-L6 DRGs with the corresponding spinal cord segments 
and the sciatic nerves were rapidly dissected out and either frozen at -80°C for western blot 
and RT-PCR analyses or fixed by immersion in freshly prepared 4% phosphate-buffered 
paraformaldehyde, pH 7.3, for 4–6 h at 4°C, and then rinsed overnight in 0.1 M phosphate 
buffer (PB), pH 7.3, containing 20% sucrose for immunohistochemistry. After sucrose 
infiltration, samples were embedded in Optimal Cutting Temperature (OCT) medium for 
cryostat sectioning. 
 
4.4 Immunohistochemistry 
 
A total of 36 DRGs and lumbar spinal cord segments were processed: 16 from the acutely 
treated group (8 bortezomib-treated, 8 controls) and 20 from the chronically treated ones 
(10 bortezomib-treated, 10 controls). Sixteen sciatic nerve segments, 8 from the acutely 
treated group (4 bortezomib-treated, 4 controls) and 8 from the chronically treated ones (4 
bortezomib-treated, 4 controls), were examined. Cryostat semiconsecutive sections (12 μm 
thick) were collected on chrome alum-gelatin (USB Corporation, Cleveland, OH, USA) 
coated slides and processed either by the avidin–biotin–peroxidase complex (ABC) 
immunohistochemical technique or by immunofluorescence double labeling.  
 
4.4.1. ABC Immunohistochemical technique  
 
For ABC processing, endogenous peroxidase activity was blocked with 0.1% 
phenylhydrazine in phosphate buffered saline (PBS) containing 0.2% Triton X-100 
(PBS/T) followed by incubation with 20% of either normal goat (NGS) or normal horse 
serum (Vector, Burlingame, CA, USA) for 1h at RT and then incubated with primary 
antiserum (cfr Table 5). 
Biotin-conjugated goat anti-rabbit, donkey anti-goat, and goat anti-guinea-pig serum 
(Vector, Burlingame, CA, USA), diluted 1:400, were used as secondary antiserum. The 
reaction product was revealed by the ABC complex (BioSpa Div. Milan, Italy), diluted 
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1:250, and followed by incubation with a solution of 0.1 M PB, pH 7.3, containing 0.05% 
3-3′-diaminobenzidine (Sigma, Milan, Italy), 0.04% nickel ammonium sulfate and 0.01% 
hydrogen peroxide.  
 
4.4.2 Indirect immunofluorescence  
 
For IF the slides were incubated with either 20% normal goat (NGS) or normal horse 
serum (Vector, Burlingame, CA, USA) for 1 h at RT then incubated with primary 
antiserum overnight at 4C (cfr Table 5). 
For double labeling, after a pre-incubation with 20% NGS, sections were double stained 
for TRPV1/CGRP, TRPV1/SP by means of subsequent incubations with primary 
antiserum, diluted as reported in Table 3. Sections were then incubated with Alexa Fluor 
488- or Alexa Fluor 594-conjugated secondary antibodies (Invitrogen, Eugene, OR, USA), 
diluted 1:500 and 1:600, respectively. Control immunostaining was obtained substituting 
the primary antiserum with normal serum. Slides were examined with an Olympus BX61 
microscope, equipped with epifluorescence illumination, and digital images were captured 
with a Leica DF 450C camera 
 
4.4.3 Morphometry 
 
Morphometric analysis, carried out by the same examiner blinded to animals’ treatment, 
was performed on DRG neuronal cell profiles in digital images captured with a 20x 
objective magnification from 10 to 12 animals out of the acutely and chronically treated 
groups, respectively. The tissue sections were separated by at least 108 μm and only cells 
that obviously showed the nuclear profile were considered. Neuronal mean diameters were 
automatically measured by ImageProPlus software. Statistical parameters (mean, 
minimum, maximum, S.D.) and histograms of the neuron sizes, processed as a pool, were 
obtained by Statistica 6 software. The percentage of DRG immunostained perikarya, 
processed as a pool, was calculated as the ratio of the total number of labeled cells found in 
four to eight sections to the total number of cells found in the same sections after a 
modified Mayer's hematoxylin [certified hematoxylin (1.0 g/l), sodium iodate (0.2 g/l), 
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aluminum ammonium sulfate·12 H2O (50 g/l), chloral hydrate (50 g/l) and citric acid (1 
g/l) counterstaining. 
 
4.4.4 Image densitometry 
 
For the quantitative evaluation of SP, CGRP and TRPV1 immunohistochemical labeling in 
the dorsal horn of the spinal cord, 6 representative 10x magnification microscopic fields 
for each marker (three bortezomib-treated animals and three controls) were blindly 
analyzed with ImageJ (http://rsb.info.nih.gov/ij/). Mean gray values from negative controls 
were subtracted from the gray values of the immunostained sections to exclude background 
staining. Histograms were obtained by calculating the ratio of bortezomib-treated values to 
control values.  
 
4.5 Protein and RNA extraction 
 
A total of 32 DRGs and spinal cord segments were analyzed: 12 from the acutely treated 
group (6 bortezomib-treated, 6 controls) and 20 from the chronically treated group (10 
bortezomib-treated, 10 controls). Total protein and RNA from DRGs and spinal cord tissue 
were isolated by the TRIzol® method (Invitrogen, Carlsbad, CA) (1 ml/100 mg of tissue), 
the samples were homogenated with TRIzol® using.polytron and followed by addition of 
chloroform (200 µl/ml of TRIzol®), the tubes were inverted vigorously by handin then 
incubeted for 5 min at room temperature (RT). After centrifugation at 12000*g for 15 min 
at 4°C protein and RNA were separated into a lower organic phase and an upper aqueous 
phase, respectively.  
 
4.5.1 Protein extraction  
 
The organic phase was incubated in absolute ethanol (EtOH) (300 µl/ml of TRIzol® used 
for the initial homogenization) for 2-3 min at RT followed by centrifugation at no more 
than 2000 * g for 5 min at 4°C. The supernatant was then combined with isopropyl alcohol 
(1.5 ml/ml of TRIzol® used for the initial homogenization), incubated for 10 min at RT, 
and then centrifuged at 12000 * g for 10 min at 4°C. The supernatant was withdrawn 
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and the protein pellet was washed 3 times in a solution containing 0.3 M guanidine 
hydrocloride (IBI scientific, Kapp Court, Peosta, IA, USA) in 95 % EtOH (2 ml/ml of 
TRIzol® used for the initial homogenization) then after 20 min incubation centrifuged at 
7500 * g for for 5 min at 4°C, this procedure was repeated for ech wash cycle.  
After the final wash the protein pellet was vortexed in asbolute EtOH (2ml) and stored 
for 20 min at RT, finally was centrifuged at 7500 * g a for 5 min at 4°C. Samples were 
then resuspended in distilled water containing 2% sodium dodecilsulfate (SDS) (300 
μl/100 mg of initial tissue). Protein concentrations were determined using the Lowry 
protein assay with bovine serum albumin as the standard. 
 
4.5.2 RNA extraction 
 
The aqueous phase was transferred into a fresh tube, the organic phase was saved for 
protein extraction. In the fresh tube was added isopropyl alcohol (0,5 ml/ml of TRIzol® 
used for the initial homogenization) and incubated for 10 min at RT, then centrifuged at no 
more than 12000*g at 4°C for 10 min to allow RNA precipitation. The RNA precipitate 
form a gel like pellet on the side and bottom of the vial. 
The supernatant was removed and RNA-pellet was washed once with 75% of Ethanol 
in RNase-free (RF) diethyl pyrocarbonate (DEPC) water (1ml/ml of TRIzol®used for the 
initial homogenization), the mix was vortexed and centrifuged at no more then 7500*g 
for 5 min. at 4°C. 
At the end of the procedure the RNA-pellet was briefly dryed (air dry) for 5-10 min 
then was risuspended in DEPC RF water.  
The quantity and purity of the RNA was assessed using both nano-volume 
spectrophotometer (Nanophotometer P-360 Implen GmbH, München, Germany) and 
electrophoresis technique in 2% agarose gel in TAE. 
TAE preparation 
For 1 liter of 50x TAE buffer use: 
242 g Tris base (2-amino-2-hydroxymethyl-propane-1,3-diol) (= 2 moles) 
57.1 mL glacial acetic acid (= 100% acetic acid) (57.19 mL = 1 mole) 
100 mL 0.5 M Na2 EDTA (pH 8.0) 
Pour H2O to reach a total volume of 1 L. 
To prepare 0.5 M Na2EDTA (pH 8.0) add 186.1 g of disodium ethylene 
diamino tetraacetate in ddH2O up to 800 ml of H2O. Adjust the pH to 8.0 with 
NaOH (20 g approx. NaOH). Solution must be sterilized by autoclaving.  
  
73 
 
4.6 Western blot 
 
Total proteins (40 μg) were separated by SDS-polyacrilamide gel electrophoresis (SDS-
PAGE) using a 10% (w/v) polyacrilamide resolving gel. Internal molecular weight (mw) 
standards (Kaleidoscope Prestained Standards, Bio-Rad, Hercules, CA, USA) were run in 
parallel. Two gels were run simultaneously for Coomassie staining and immunoblotting. 
Proteins for immunoblotting were electrophoretically transferred to a polyvinylidene 
fluoride membrane (Bio-Rad, Hercules, CA, USA) using the Mini Trans Blot Cell (Bio-
Rad, Hercules, CA, USA). Blots were blocked by immersion in 20mM Tris base and 
137mM sodium chloride (TBS) containing 5% milk powder and 0.1% Tween 20 (TBS-T), 
for 60 min at room temperature and incubated overnight at 4 °C with a rabbit polyclonal 
primary antibody against TRPV1 (cfr Table 5) (Abcam, Cambridge, UK), diluted 1:1000 
in TBS containing 5% milk powder and 0.2% NaN3 (Sigma, Milan, Italy). After a TBS-T 
rinse, blots were incubated for 60 min, at room temperature, with peroxidase-conjugated 
goat anti-rabbit serum (Sigma Aldrich, St Luis, MO, USA), diluted 1:10000 in TBS/T. 
Loading controls were obtained by stripping and immunostaining the membranes as above, 
using a monoclonal mouse antibody against glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (Chemicon, Temecula, CA, USA), diluted 1:1000, as the primary antiserum, 
and a peroxidase-conjugated goat anti-mouse serum (Chemicon, Temecula, CA, USA), 
diluted 1:5000, as the secondary antiserum. To control for non specific staining, the blots 
were stripped and incubated with the relevant secondary antiserum. After a TBS-T rinse, 
protein bands were visualized on an autoradiograph (Kodak X-Omat LS, Kodak, 
Rochester, NY) using the ECLTM Prime reagents (GE Healthcare, Buckinghamshire, UK). 
The approximate mw of immunolabelled protein bands was determined by means of 
Molecular Analyst© Software (Version 1.4, Bio-Rad Hercules, CA, USA) by comparing 
the position of relevant bands on the autoradiograph film with that of nearby prestained 
mw standards. Relative optical density (O.D.) was quantified by means of the GS800™ 
Calibrated Densitometer and the Quantity One 1 (Bio-Rad, Hercules, CA, USA) 
software.  
  
74 
 
4.7 RT-PCR 
 
For each sample: the total RNA was treated with RNase-free DNase I (RQ1, Promega 
Corporation, Madison, WI, USA) for 20 min at 37°C. cDNA was then synthesized 
following a two-step RT-PCR proctol from Enhanced Avian HS RT-PCR Kit (Sigma-
Aldrich® , St. Luis, MO, USA)  
1) optional step (this step may denature RNA secondary structure, which will allow 
for more efficent reverse transcription): in a fresh RNase-free tube the following 
reagents were added 
 
Volume Reagent Final concetration 
1 µl Deoxynucleotide mix 500 µM each dNTP 
1 µl Anchored oligo (dT)23 3.5 µM 
100 ng RNA template 0.005-0.250µg/µl total 
RNA 
q.s Water, PCR reagent - - - - - - - - - - -- - - 
10 µl final volume 
 
 The reaction mix was mixed gently and briegly centrifuged to collect all 
components at the bottom of the tube than incubated in thermocycler for 10 min at 
70°C. The tube was removed and placed on ice. 
2) Reverse transcription: the tube was centrifuged and added the following 
components: 
 
Volume Reagent Final concetration 
6 µl Water, PCR reagent  
2 µl 10X buffer for AMV-
RT 
1X 
1 µl RNase inhibitor 1 U/ µl 
1 µl Enchenced Avian RT 1 U/ µl 
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20 µl final volume 
 
The tube was incubated in thermocycler for 50 min at a temperature between 42-
50°C. The first strand of cDNA is now ready for subsequent PCR amplification. 
 
4.7.1 PCR amplification 
 
Hot start PCR was performed using 2X Taq DNA Polymerase Master Mix (VWR 
International, Geldenaaksebaan, Belgium), containing  
 150 mM Tris-HCl pH 8.5, 40 mM(NH4)2SO4, 3 mM MgCl2, 0.2% Tween 20® 
 0.4 mM dNTP  
 0.05 U/μl Ampliqon Taq DNA-polymerase Stabilizer 
For PCR amplification, specific primers for TRPV1, CGRP and Beta-actin mRNAs were 
designed using the http://www.premierbiosoft.com/netprimer/ open source software. Each 
cDNA was amplified twice. Amplification of the β-actin housekeeping gene and mw DNA 
Ladder (VWR international, Geldenaaksebaan, Belgium) were run in parallel.  
 
Primer sequences for RT-PCR 
 
mRNA Primer sequences Amplification product 
TRPV1 Forward: 5’-gcactcctccctttatgac-3’ 
Reverse: 5’-gccgatggtgaacttgaac-3’ 
686 bp fragment  
(NCBI Ref. sequence: NM_031982.1) 
CGRP Forward: 5’-ctctcagcagcatgtgggt-3’  
Reverse: 5’-taactcatttatacttggtttca-3’ 
554 bp fragment  
(NCBI Ref. sequence: NM_138513.1) 
β-actin Forward: 5’-ccagagcaagagaggcatc-3’  
Reverse: 5’-gtccctgtat gcctctggt-3’ 
265 bp fragment  
(NCBI Ref. Sequence: NM_031144.2) 
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After setting the parameters and the optimum conditions for the different primers,in 
clean vials were prepared mix PCR reaction with the following reagents: 
 
Volume Reagent Final concetration 
10 µl 2X Taq Master Mix 1X 
1 µl Forward Primer 0.25 µM 
1 µl Reverse Primer 0.25 µM 
7 µl Distilled Water  ----------------- 
1 µl cDNA template 100 ng 
20 µl Final Volume 
 
The PCR was performed according to the following procedure: 95°C for 3 min, 30-40 
cycles 95°C for 30 sec, 54/56°C for 1 min, 72°C for 30 sec, final elongation at 72°C for 10 
min. PCR products were then separated by electrophoresis in a 1.5% agarose gel in TAE 
buffer containing GelRed (Biotium, Hayward, CA, USA). cDNA bands were visualized 
by means of an ultraviolet transilluminator (UVP PhotoDoc-ItTM Imaging System) and 
digital images of the gel were acquired with a Canon PowerShot A480 camera. The 
approximate mw of amplification products and relative O.D. was determined on digital 
images using ImageJ Software (http://rsb.info.nih.gov/ij/) by comparing the position of 
relevant bands to that of nearby mw standards. 
 
4.8 Statistical analysis 
 
The differences in body weight and behavioral data were statistically evaluated using the 
unpaired Student’s t test (significance level set at p < 0.05). Paired Student’s t-test was 
used for comparing differences between percent frequencies of DRG labelled neurons, 
relative frequencies of neuronal size groups and grey levels. One-way ANOVA and the 
Fisher’s test for post hoc analyses were applied to evaluate statistical differences among 
groups in the western blot and RT-PCR analysis.  
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Table 5. List of antibodies used for immuhistochemistry and western blot 
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